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In summary, NIDDM most often develops in subjects at a rather advanced 
age, wherein the enthusiasm for a life-long physical exercise regime might 
be fairly limited … 
Is the conclusion then that physical exercise as therapy for NIDDM is 
theoretically interesting, but practically not feasible? 
The questions will then arise about the possibility of reaching sufficient 
intensity in such a group and whether non-intensive exercise (e.g., walking 
or golf) is effective. Unfortunately there is very little data on these points. 
Professor Per Björntorp (1931–2003), in Diabetes Care 1992 
(NIDDM = Non-insulin-dependent diabetes mellitus,  
today known as type 2 diabetes mellitus.) 
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ABSTRACT 
Background and aim Type 2 diabetes mellitus (T2DM) is a disease associated with the 
risk of severe cardiovascular complications. Genetic predisposition, a sedentary life-
style and overweight may increase the risk of developing T2DM. The aim was to study 
the effects of physical activity on risk factors of cardiovascular disease, health-related 
quality of life, and on the gene expression of enzymes involved in glucose and lipid 
metabolism, in overweight people with T2DM, impaired or normal glucose tolerance.  
Methods Two different exercise intervention studies were conducted, both for a four-
month period. Study 1, presented in paper I, included 52 T2DM patients, 26 controls, 
26 in an intervention group. The intervention was to increase physical activity by brisk 
walking, 45 minutes three times per week. At baseline and after four months we 
assessed systolic (SBP) and diastolic (DBP) blood pressure, body mass index (BMI), 
glucose and lipid metabolic parameters, self-reported physical activity and physical 
fitness. Study 2 (papers II, III and IV) included 212 overweight individuals. The 
intervention was a weekly physical activity increase by 5 hours of walking with 
walking poles (Nordic walking). The participants were classified by an oral glucose 
tolerance test (OGTT) with normal glucose tolerance (NGT), impaired glucose 
tolerance (IGT) or type 2 diabetes mellitus (T2DM), and randomized into a control 
group (n=125), or an exercise intervention group (n=87). Health-related quality of life 
(HRQoL) was recorded by questionnaire (paper II), and anthropometric and clinical 
data (papers II & III) were assessed at the time of inclusion and after four months. 
From 79 NGT and 33 T2DM male exercise participants a 20–100 mg biopsy was taken 
from the quadriceps muscle of the thigh, for the assessment of messenger RNA 
(mRNA) expression of mitochondrial genes, coding for enzymes involved in glucose 
and fatty acid metabolism (paper IV).  
Results In study 1 there were no significant improvements of anthropometric 
parameters, physical fitness, blood pressure, glucose or lipid metabolism. The 17 
patients in the intervention group who attained ≥80% of the intended increment of 
physical activity significantly improved SBP, DBP, BMI and total plasma cholesterol, 
compared with the control group. In study 2 (papers II & III) quality of sleep, body 
weight, BMI and waist circumference were improved for NGT exercise participants, 
and in the IGT exercise group exercise capacity improved. Among the exercise 
participants ≥80% compliant with the scheduled time of Nordic walking, exercise 
capacity improved significantly in all three (NGT, IGT and T2DM) exercise groups. 
Blood pressure, glycaemic control and blood lipids were unaffected. Baseline mRNA 
expression of 3 mitochondrial genes was increased in the T2DM group (paper IV). In 
the NGT group the expression of the enzyme PDK4 was increased after the exercise 
period, but not in the T2DM group. 
Conclusions The exercise participants ≥80% compliant with the exercise goals in paper 
I improved SBP, DBP and BMI. The exercise goal of Nordic walking, 5 hours per 
week, led to improved quality of sleep, body weight, BMI and waist circumference in 
the NGT group, and exercise capacity improved in the IGT group. The elevated 
baseline PDK4 expression and the unaltered post-exercise expression in the T2DM 
cohort may reflect an impaired utilization of glucose and lipid fuels inherent in T2DM, 
and a dysfunction of the appropriate adaptive responses to exercise in skeletal muscle 
associated with insulin resistance.  
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ABBREVIATIONS AND DEFINITIONS 
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MID Minimally important differences 
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PRO Patient-reported outcome(s) 
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INTRODUCTION 
 
Diabetes mellitus is a chronic disease signified by a pathologically increased level of 
glucose in the blood (hyperglycaemia). This diagnosis comprises several conditions of 
different pathogenic origins. The underlying cause of hyperglycaemia is either lack of 
insulin or the impaired effect of insulin in target tissues.  
CLASSIFICATION 
Diabetes is primarily classified as type 1, type 2, gestational or secondary diabetes. The 
focus in the studies presented in this thesis is on type 2 diabetes only, but the other 
main types of diabetes are briefly described below.  
Type 1 diabetes and LADA 
Type 1 diabetes is an autoimmune disease caused by the formation of antibodies 
directed against the insulin-producing beta cells of the pancreas. The destruction of beta 
cells caused by the antibodies leads to the cessation of endogenous insulin production. 
The treatment of type 1 diabetes is therefore daily insulin injections. The onset is 
typically in childhood or early adolescence, but it can develop at any age, and 
hyperglycaemia develops rapidly, and to levels that can be life-threatening if not 
promptly treated. Latent autoimmune diabetes in adults (LADA) is an autoimmune type 
of diabetes affecting adults, usually with a more gradual development of insulin 
deficiency than is the case in “classical” type 1 diabetes. Insulin treatment may 
therefore not be necessary at the onset of LADA, and oral glucose lowering agents may 
initially suffice to maintain good glycaemic control. However, insulin deficiency 
usually occurs in one or a few years’ time.  
Type 2 diabetes 
Type 2 diabetes has a more insidious onset than type 1 diabetes, and blood glucose 
rarely reaches life-threatening levels. It has by tradition been considered a disease of 
middle or old age. In recent years, however, type 2 diabetes has become a frequent 
diagnosis also in young people, particularly in the United States of America [1,2]. Type 
2 diabetes is caused by a combination of resistance to the metabolic effects of insulin in 
various tissues and an insufficient insulin secretion [3]. The result is impaired glucose 
metabolism and hence a fuel deficit in cells that depend on glucose as a major source of 
energy. The level of circulating glucose in the blood is elevated but unavailable to the 
cells of various organs. The diabetic condition has therefore been characterized as 
“starvation in the midst of plenty”.  
Insulin resistance seems to appear early in the development of this disease. Skeletal 
muscle, liver and adipose tissue are the main organs affected by insulin resistance. A 
pre-diabetic state of impaired glucose tolerance and a low degree of hyperglycaemia 
(impaired fasting glucose) may be present for a long period of time before the onset of 
overt diabetes and may cause changes in various tissues, but without clinical symptoms. 
At the time of inclusion in the United Kingdom Prospective Diabetes Study, 38% of 
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3041 newly diagnosed type 2 diabetes patients had developed diabetes retinopathy to 
some degree [4]. A family history of T2DM, old age, a sedentary lifestyle and obesity 
are all associated with an increased risk of developing T2DM. In addition to obesity 
and deranged glucose metabolism, T2DM is often associated with elevated blood 
pressure (hypertension) and a disturbed metabolism of blood lipids (dyslipidaemia). 
The term “metabolic syndrome” has been used to draw attention to this cluster of 
cardiovascular risk factors, which is often present in patients with type 2 diabetes. It is 
not known whether these factors interact or whether the metabolic syndrome per se 
implies an increased risk of cardiovascular disease and the development of type 2 
diabetes [5].  
Lifestyle intervention, involving physical activity and reduced caloric intake, has 
been shown to prevent, or delay, the development of impaired glucose tolerance into 
overt T2DM [6-8]. Moreover, other studies have shown that people with and without 
T2DM who are physically active, or who adopt a more physically active lifestyle, have 
a longer life expectancy[9-12]. In a joint position statement the American College of 
Sports Medicine and the American Diabetes Association conclude that regular exercise 
is considered to play “a major role in the prevention and control of insulin resistance, 
pre-diabetes, gestational diabetes mellitus, type 2 diabetes and diabetes-related 
complications” [13]. 
Gestational diabetes 
Gestational diabetes develops during pregnancy. It is caused by insulin resistance and 
not by an autoimmune reaction. It is thus classified as type 2 diabetes and usually 
subsides after delivery. Women who have had gestational diabetes are at high risk of 
developing type 2 diabetes later in life [14]. 
Secondary diabetes 
Secondary diabetes can be caused by various factors, other than insulin resistance or the 
formation of autoantibodies. Diseases of the pancreas, predominantly pancreatitis, may 
result in extensive destruction of insulin-producing beta cells and the development of 
insulin-dependent diabetes. Various drugs, particularly corticosteroids, may after long-
term treatment cause the development of T2DM as an undesired side effect. 
Insulin and its effects  
Insulin is synthesized in the beta cells of the islets of Langerhans in the pancreas. It is 
released from the beta cells into the blood, and the amount of insulin released is 
regulated by the levels of blood glucose. Insulin is the most important anabolic 
hormone in the human body. Its effects are of vital importance for the regulation of 
carbohydrate, lipid and protein metabolism. The main target organs for the effects of 
insulin are skeletal muscle, the liver and adipose tissue. Insulin mediates the uptake of 
glucose from the blood into the cells of the various organs, where glucose is utilized as 
fuel for metabolic processes. Glucose is, in fact, the main substrate for energy 
production in the human body. When bound to an insulin receptor in the cell membrane 
of the target organ, insulin mediates several intracellular effects. A glucose transporter 
protein (GLUT) facilitates the uptake of glucose across the cell membrane, into the cell. 
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There are 13 different isoforms of glucose transport proteins and GLUT4 is 
predominant in skeletal muscle cells [15]. Translocation of GLUT4 from the 
intracellular cytosol to the cell membrane, where it exercises its effect, is an insulin 
effect but GLUT4 translocation is also an effect of muscle contraction [16]. 
Furthermore, insulin triggers a cascade of intracellular enzymatic reactions involved in 
the oxidation of glucose. In adipose tissue the anabolic effect of insulin is mediated by 
its lipolytic effects and the storing of triglycerides. 
Impaired insulin sensitivity, or insulin resistance, is a metabolic disturbance that 
precedes the development of overt type 2 diabetes [17]. Although the nature of insulin 
sensitivity is not fully understood it can be measured [18], and it is well established that 
it can be enhanced by regular physical exercise [19]. Exercise improves the 
redistribution of GLUT4 to the cell membrane, a factor that seems to contribute to 
improved insulin sensitivity, whereas this GLUT4 translocation to the cell membrane is 
impaired in insulin resistance [20]. Furthermore, the dysregulation of certain enzymes 
involved in the oxidation of carbohydrates and fatty acids in the mitochondria of the 
skeletal muscle cell may contribute to insulin resistance [21]. Diminished activity of 
several oxidative enzymes present in the mitochondria, and involved in carbohydrate 
and lipid oxidation, has been described [21]. This impaired lipid oxidation causes an 
accumulation of triglycerides in skeletal muscle cells which seems to be correlated with 
the degree of insulin resistance [22]. Healthy skeletal muscle cells with normal insulin 
sensitivity have the capacity for a metabolic shift from utilizing glucose as energy 
substrate in the fed, insulin-stimulated state, to the use of fatty acids as a fuel source in 
the fasting state. This metabolic flexibility between carbohydrates and lipids as sources 
of energy is less pronounced in insulin-resistant skeletal muscle, indicating the 
impairment of both carbohydrate and lipid metabolism in insulin resistance and type 2 
diabetes [23]. At the onset of type 2 diabetes insulin sensitivity is impaired, as is the 
endogenous production of insulin. Initially it is the rapid elevation of plasma insulin 
levels following the ingestion of food that is impaired. With increasing diabetes 
duration the beta cell function tends to diminish with a general decline of insulin 
production. This may develop, over a period of several years, into the cessation of 
insulin production.  
TYPE 2 DIABETES 
Diagnosis 
Diabetes is diagnosed by the assessment, on two different occasions, of elevated plasma 
glucose levels, measured in the fasting state. According to the current World Health 
Organization (WHO) diagnostic criteria, plasma glucose levels between 6.1 and 6.9 
mmol/l are classified as impaired fasting glucose, whereas ≥7.0 mmol/l is a diabetic 
level. Diabetes can also be diagnosed by an oral glucose tolerance test (OGTT), 
performed after an overnight fast. After assessing fasting plasma glucose a solution of 
75 g of glucose is ingested. A second plasma glucose assessment is performed after two 
hours. A two-hour OGTT value of ≥11.1 mmol/l is diagnostic of diabetes (≥12.2 
mmol/l if capillary blood samples are being used). The plasma glucose level at the time 
of diagnosis does not indicate the type of diabetes that has been diagnosed.  
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Epidemiology 
The prevalence of diabetes shows considerable geographic variation and increases in an 
ageing population. Since the end of the 20th century type 2 diabetes has been 
increasing on a global level, a phenomenon that has been named the diabetes pandemic. 
This rapid development is most pronounced in the Middle East, Asia, Africa and South 
America and is probably caused by a “westernized lifestyle” comprising less physical 
activity and excessive dietary intake of fat and carbohydrates. Overweight and/or 
obesity are known to be strong risk factors for T2DM in both men and women[24,25]. 
WHO estimates indicate that the prevalence of diabetes in adults will rise on a 
worldwide basis from 135 million in 1995 to 300 million in 2025 [26]. More recent 
data indicate that the global diabetes prevalence will continue to increase, even if levels 
of obesity remain constant, and the number of people with diabetes is estimated to rise 
to 366 million in 2030 [27]. 
An increasing number of young persons with pronounced adiposity develop type 2 
diabetes, particularly in Japan and the United States [1,2]. This is an alarming 
development that may become a global reality due to the ongoing increase of mean 
BMI in the western world as well as in developing countries, a tendency that applies to 
all age groups.  
T2DM is evenly distributed between males/females in most populations. During the 
first half of the 20th century T2DM was more prevalent among females, but this has 
shifted towards a more equal sex distribution. In some populations a male 
preponderance was noted during the latter half of the 20th century, possibly as a 
consequence of the increasing obesity in men, characterized by abdominal fat 
distribution [28].  
The total prevalence of diabetes in Sweden is approximately 4.5% according to 
recent surveys, with a slight dominance of men [29,30]. In the age group >75 years the 
prevalence was 16% in one survey [29]. Type 2 diabetes represents 85–90% of all 
diabetes in Sweden. It is usually a disease with mild or no symptoms at all, unless 
blood glucose rises to very high levels or acute cardiovascular complications occur. 
The patient with type 2 diabetes can therefore be undiagnosed for a variable amount of 
time, probably for years in some cases. The prevalence of type 2 diabetes in a 
geographic area in our country most likely depends on whether or not active screening 
for this disease is performed in the area.  
Complications 
Type 2 diabetes is a multifaceted disease that entails the risk of impaired function and 
medical complications in several organs of the human body. The basis of such 
complications is atherosclerotic changes in blood vessels and subsequent impairment of 
blood circulation in affected organs. Hyperglycaemia, hypertension and dyslipidaemia 
often co-exist in type 2 diabetes and constitute the three central risk factors of late 
diabetes complications, so called since they often occur after years of diabetes duration. 
Most common in type 2 diabetes are the macro-vascular complications, emanating from 
the great blood vessels, affecting the heart and central nervous system, causing angina 
pectoris, acute myocardial infarction or stroke. These complications are often disabling 
or lethal in their consequences. The micro-vascular complications, emanating from 
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capillaries, may affect the retina of the eyes, the kidneys and the feet, causing visual 
impairment, renal failure and ulcerations of the feet. 
Management  
It has hitherto not been possible to find a curative treatment of type 2 diabetes, and the 
three main aims of diabetes care are therefore the absence of hyperglycaemic 
symptoms, the maintenance of good quality of life and the prevention of late diabetes 
complications. Regulating blood glucose [4], blood pressure [31] and blood lipid levels 
[32] to as near normal as possible reduces the risk of diabetes complications. Medical 
monitoring of type 2 diabetes in Sweden is mainly undertaken in primary health care. 
Primary health care therefore has an important function in educating and supporting 
patients with type 2 diabetes in disease management, as well as in preventing the 
development of T2DM in patients at risk. 
Management of type 2 diabetes comprises a combination of pharmacological 
treatment and lifestyle alterations. It is therefore important to assess the possible effects 
of non-pharmacological aspects of diabetes treatment and to develop methods of 
conveying to the patient possible means of individually adapted lifestyle alterations.  
Changes of dietary habits and increased regular physical exercise are lifestyle 
changes most commonly called for in type 2 diabetes. It is often difficult, however, to 
attain satisfactory levels of blood glucose, blood pressure and blood lipids by means of 
lifestyle alterations only. In the Steno-2 study it was possible to improve the levels of 
blood glucose, blood pressure and blood lipids, as well as the risk of cardiovascular 
complications, in patients with type 2 diabetes during 7.8 years of intensive medication 
[33]. With increasing duration of type 2 diabetes, the difficulty of maintaining 
satisfactory blood glucose control usually becomes more pronounced.  
Pharmacological treatment  
Pharmacological treatment of type 2 diabetes involves oral drugs that enhance the 
endogenous production of insulin or drugs that improve insulin sensitivity, often in 
combination. Incretins represent a class of anti-diabetic drugs that have been recently 
introduced for clinical use. They enhance postprandial insulin secretion and inhibit 
gastric motility. This delays and protracts carbohydrate absorption and contributes to a 
satiating effect. Incretin drugs can be administered orally (Dipeptidyl peptidase-4 
inhibitors) or as subcutaneous injections (Glucagon-like peptide-1 analogues) [34]. 
With decreasing insulin production oral medication becomes less efficient in 
maintaining adequate blood glucose control. Insulin injections are then the 
recommended mode of treatment. Patients with type 2 diabetes usually require higher 
doses of insulin than patients with type 1 diabetes. This is due to the presence of insulin 
resistance in type 2 diabetes, which does not occur in type 1 diabetes. It has not been 
possible to prevent, or slow down, the progression of insulin resistance or the 
diminishing insulin production in type 2 diabetes. Despite high doses of oral anti-
diabetic drugs or insulin, given as subcutaneous injections, it may be difficult to attain 
adequate blood glucose levels with an increasing duration of type 2 diabetes. 
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Non-pharmacological treatment 
Physical exercise  
A sedentary lifestyle seems to be a contributory factor in the development of insulin 
resistance and type 2 diabetes [6,8,35,36]. Skeletal muscle cells at work derive most of 
their energy from the oxidation of glucose [19]. The amount of physical activity 
therefore plays an important role in glucose metabolism. At the same time our 
knowledge is insufficient as to the amount – in terms of time, intensity and mode – of 
exercise that is required to obtain measurable health effects. 
Regular physical exercise is known to have cardiovascular risk-reducing effects in 
the treatment of type 2 diabetes, hypertension and hyperlipidaemia [37-39]. Studies on 
exercise in diabetes have, however, often been performed on relatively young persons 
and involved rather intensive exercise programmes. Many patients with type 2 diabetes 
are unaccustomed to exercising, middle-aged or elderly and overweight. A 6 month 
structured exercise and support programme was not effective in increasing physical 
activity in sedentary patients with type 2 diabetes, aged 60±8 years [40]. In an article 
reviewing 14 studies of exercise in obese patients with type 2 diabetes, it was 
concluded that glucose metabolic control did not improve in type 2 diabetes patients 
aged 57 to 61 years, as it did in type 2 diabetes patients aged 40 to 54 years [41]. 
Sedentary type 2 diabetes patients thus appear to be less prone to start exercising at age 
≥60 than at the age of 40 to 50+. On the other hand, two studies with participants aged 
54–58 years have reported good adherence to one 3-year diet-and-exercise intervention 
and one 12-week walking programme [42,43]. Anthropometric and metabolic 
parameters were improved in both studies and in the walking study estimated VO2max 
improved as well.  
This large group of patients could probably benefit in several respects from adopting 
habits of regular physical activities that are adapted to their abilities. Providers of 
diabetes care may have limited practical knowledge and lack the methodological 
routines required to help patients to establish feasible exercise habits and to 
demonstrate the different effects of exercise activities [44]. It is therefore important to 
obtain practical experience of the effects of low or medium intensive exercise in the 
treatment of type 2 diabetes. 
Dietary recommendations 
Current Swedish dietary guidelines for diabetes patients [45] recommend a restriction 
of saturated fat to 10 E% and carbohydrates to 50–60 E%. The subject of recommended 
proportions of carbohydrate versus fat intake has caused substantial controversy over 
the past few years. The scientific evidence has been considered to be insufficient for a 
definite recommendation of the preferred intake of carbohydrates and fat in the general 
population as well as in type 2 diabetes.  
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SIGNIFICANCE TO PATIENTS AND COMMUNITY  
Patients 
Primary health care has an important task in counselling patients with type 2 diabetes 
so that they can manage their disease in an optimal way, thereby reducing the risk of 
late diabetes complications. It is also important to develop cost-effective means for the 
management of type 2 diabetes. If diabetes complications can be prevented, much 
human suffering can be avoided, as well as expensive efforts at medical rehabilitation. 
Furthermore, patients with type 2 diabetes experience lower health-related quality of 
life (HRQoL) than the general population [46,47]. Low HRQoL in type 2 diabetes is 
due mainly to the presence of diabetes complications. Medication as well as alterations 
of lifestyle may, however, also impair HRQoL. It is therefore important to consider 
aspects of quality of life when making recommendations for diabetes treatment. It is 
well known that the development of T2DM can be prevented, or delayed in people with 
impaired glucose tolerance [6,8]. This is a group of patients that can easily be identified 
in primary health care, and one that can benefit from professional counselling on the 
diabetes-preventive effects of regular exercise and weight reduction. In one study it was 
reported that only 25% of patients with type 2 diabetes discussed matters of exercise 
with health care professionals. Very few patients reported receiving specific guidelines 
regarding the type, frequency or duration of exercise [44].  
Costs of diabetes care 
Direct medical costs for the care of patients with type 2 diabetes in Sweden were 
estimated at approximately 7 billion SEK in 1998 according to the CODE-2 study [48]. 
CODE-2 compared the costs of medical care of type 2 diabetes in eight European 
countries. The number of Swedish patients included in the study was 777. The annual 
per-patient cost was estimated at 25,000 SEK, representing 6% of Swedish health care 
expenditure in 1998. The largest share (42%) represented costs for hospital care 
whereas 31 and 27% represented costs for ambulatory care and medication, 
respectively. Treatment costs were more than three times higher if the patients had 
micro- and macro-vascular complications.  
Lifestyle alterations in patients – a challenge to medical care providers 
and epigenetic research  
The initial cause of my personal interest in type 2 diabetes and physical activity was a 
frustration with the difficulties of helping my patients to make lifestyle changes. It is a 
common experience in diabetes care that lifestyle changes concerning physical activity 
and dietary habits are not easily attained. Alterations of lifestyle cannot be prescribed in 
the same manner as medication. Motivation is more crucial to the implementation of 
lifestyle alterations than it is to medication. Motivation to increasing the amount of 
physical activity ideally ought to involve the demonstration of positive effects 
following exercise activities. In a public health perspective such effects should be 
measurable after a reasonably short period of regular exercise that can be performed by 
people not previously accustomed to exercising. 
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In a pilot study we demonstrated an acute blood glucose lowering effect of 2.2 
mmol/l following brisk walking [49]. This post-walk decrement is short-lived, 
however, and blood glucose levels rise promptly after the ingestion of food. From a 
motivational point of view it would be relevant also to demonstrate to patients the 
possible positive long-term effects of regular walking on the different cardiovascular 
risk factors known to be connected with type 2 diabetes.  
Since type 2 diabetes is mostly an asymptomatic disease, provided that 
complications have not occurred and blood glucose levels are not excessively elevated, 
the patient seldom experiences any physical incentives to strict diabetes control. For 
that reason I also wished to investigate the effects on quality of life in connection with a 
period of regular physical activity.  
Limiting factors to physical exercise, such as pain in joints and musculature [50], 
high age and being unaccustomed to exercising are common among patients with type 
2 diabetes. Medium or low intensity exercise should therefore be preferred when 
introducing most type 2 diabetes patients to physical activity. In a study of a 1-year diet 
and exercise intervention in obese people aged ≥65 years, 93 (87%) of 107 participants 
completed the study [51]. The mode and intensity of exercise were adapted to the 
individual abilities of the participants. The demonstration of positive health effects 
following a period of regular exercise could provide pedagogical support in the 
implementation of practically oriented methods of education for patients with T2DM, 
or for people at risk of developing this disease. Reliable methods for demonstrating 
easily measurable effects of low/medium intensity exercise are lacking at present.  
The development of genetics in recent years and the technology of assessing the 
degree to which a gene is being expressed have opened new fields for research. The 
specific area of genetic research known as epigenetics describes how the expression of 
genes can be increased or decreased by factors other than changes in the sequence of 
nucleotides in the DNA molecule. Physical exercise is one factor that can alter the 
expression of certain genes involved in substrate metabolism for energy production.  
Mitochondria are intracellular organelles that play a central role in the continuous 
generation of energy in the cells. In diabetes research it has been possible to identify 
genes coding for the formation of mitochondrial enzymes that are involved in glucose 
and fatty acid oxidation. Future studies of mitochondrial gene expression may 
contribute to the understanding of the mechanisms involved in the development of 
insulin resistance and deranged glucose utilization in T2DM.  
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AIMS 
MAIN AIM 
The main aim was to study the effects of regular walking (Study 1), and Nordic 
walking with walking poles (Study 2), on cardiovascular risk factors in overweight 
people with type 2 diabetes mellitus and in those with impaired and normal glucose 
tolerance. The parameters studied were glucose metabolic control, insulin resistance, 
serum lipids and blood pressure, as well as anthropometric measurements (papers I and 
III).  
SECONDARY AIMS 
To assess the effects of Nordic walking (Study 2), on  
• self-reported health-related quality of life (paper II). 
• mitochondrial gene expression in overweight patients with T2DM and in 
individuals with normal glucose tolerance (paper IV). 
 
None of the studies included any intervention in dietary habits. 
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MATERIALS AND METHODS 
 
In study 1 patients with type 2 diabetes were enrolled from two different primary care 
practices in Gustavsberg and Saltsjö-Boo, two suburban communities outside 
Stockholm, Sweden. Public meetings, advertised in the local press, were arranged in the 
two communities and attendants were invited to participate. An additional 67 patients 
with type 2 diabetes were invited to participate when visiting their physician and 100 
by a personal letter of invitation. Patients with severe angina pectoris, physical 
disability or insulin treatment were excluded. We chose to invite the participants to the 
two groups from different communities in order to diminish the possibility that the 
patients in the control group would start exercising as they learned about the activities 
in the intervention group. This was therefore not a randomized study. 
Twenty-seven patients consented to participating in the intervention group and 31 in 
the control group. One patient in each group declined further participation shortly after 
being included in the study. Four patients in the control group were lost to follow-up, 
despite repeated reminders. Thus, the intervention group and the control group both 
consisted of 26 patients.  
The patients in the intervention group were instructed to increase their exercise by 
45 minutes of brisk walking, three times weekly, for four months. We expected this to 
be achievable by most patients. Four months was considered to be a sufficient period to 
allow for changes of the parameters under study. Walking groups were provided four 
times per week. Walking diaries and a physical activity questionnaire made it possible 
to identify those individuals who changed their level of exercise. No recommendations 
were given concerning changes in dietary habits, and medication remained unaltered in 
both groups. The patients in the control group were informed that their results were to 
be used as reference values for diabetes patients over a period of four months when no 
alterations of lifestyle or medication were undertaken. The participants were examined 
at the time of inclusion and after four months. Resting systolic (SBP) and diastolic 
(DBP) blood pressures and body mass index (BMI) were assessed. Age-adjusted 
physical fitness was determined by bicycle ergometry as a submaximal exercise test. 
Blood samples were analysed for fasting plasma glucose, insulin, glycated 
haemoglobin (HbA1c) and lipid levels (total cholesterol, HDL and LDL cholesterol and 
triglycerides). Insulin resistance was obtained from the fasting glucose and fasting 
insulin levels as HOMA-IR (Homeostasis Model Assessment) [52]. We used the 
formula HOMA IR=fasting insulin (µU/ml × fasting glucose (mmol/l)/22.5 or the 
computerized HOMA calculator for this purpose [53]. 
Blood samples and measurements of other variables in this study were obtained 
within 24–48 hours after the last exercise walk. 
 
In study 2 we included 213 individuals without severe physical or cardiovascular 
impairments aged 60±5.3 years, with body mass index (BMI) 30.2±3.8 kg/m2. 
Numbers are mean±SD. Papers II, III and IV were based on the results of study 2. 
Recruitment was achieved by advertisements in the local newspapers and by letters of 
personal invitation to 447 former participants in the Stockholm Diabetes Prevention 
Programme [54]. Based on an oral glucose tolerance test (OGTT), the participants were 
classified with normal glucose tolerance (NGT, n=128), impaired glucose tolerance 
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(IGT, n= 35) or type 2 diabetes mellitus (T2DM, n= 50). They were randomized to a 
control group with unaltered physical activity or to an exercise group performing five 
hours per week of Nordic walking with poles, for a four-month period. For the 
randomization procedure, blinded labels with the participants’ names were drawn from 
a box and assigned to either the control or intervention group. The study spanned three 
consecutive summer seasons (2006–2008), between May and September. Each year 
new entries to the study were randomized into control (unaltered physical activity) or 
intervention (Nordic walking) group. Individuals randomized to the control group were 
invited to participate in the intervention group the following year. Those who joined the 
study in both control (first entry) and intervention (second entry) groups are represented 
only once in this work, as control subjects, skewing the control/exercise group 
numbers. The control group consisted of 126/213 individuals. The intervention group 
consisted of 87/213 individuals. The use of specially designed, rubber-tipped walking 
poles activates the upper limbs while walking. In three different trials the effect of this 
additional muscle recruitment was an increase of oxygen consumption, energy 
expenditure and heart rate, compared with walking without poles. Two trials were 
conducted on a treadmill [55,56] and one on a level 200-m track [57]. Despite the 
increased oxygen consumption and energy expenditure, the participants in two of the 
trials did not report a higher rating of perceived exertion after Nordic walking than after 
walking without poles.  
Anthropometric measurements, blood chemistry, blood pressure, glucose tolerance, 
glycaemic control, insulin resistance and plasma lipids were assessed, and medication 
for diabetes, hypertension and dyslipidaemia was recorded at the time of inclusion and 
after four months.  
HEALTH-RELATED QUALITY OF LIFE ASSESSMENT 
HRQoL was assessed at the time of inclusion and after four months.  
A quality-of-life questionnaire was provided at the time of inclusion and after four 
months. The Swedish HRQoL questionnaire (SWED-QUAL) [58], adapted from the 
Medical Outcomes Study (MOS) [59], was used. MOS assessments are generic (as 
opposed to disease-specific) HRQoL questionnaires that present results as a health 
profile. The 66 items of SWED-QUAL provide the basis for 13 scales that represent the 
following aspects of HRQoL: physical functioning, satisfaction with physical health, 
pain, role limitation due to physical health, role limitation due to emotional health, 
positive affect, negative affect, cognitive functioning, sleep, general health perception, 
family functioning, marital functioning and sexual functioning. The multi-item scales 
are set between 0 and 100 points, where 0 indicates the lowest possible score and 100 
the highest. Inter-group differences of SWED-QUAL results are expressed in terms of 
statistical significance. Effect size (ES) is a complementary method for identifying 
minimally important differences (MID) of patient-reported outcomes (PRO). The MID 
is defined as the smallest change in a PRO that is perceived by the patient as beneficial. 
The effect size is defined by the formula: Effect size = (M treatment – M comparison)/SD 
pooled. An effect size of 0.2 is considered small, 0.5 moderate, and 0.8 is a large change 
[60]. An effect size of >0.4 is considered clinically relevant. SWED-QUAL has been 
used in previous studies including patients with T2DM [61,62]. A random sample of 
2500 Swedish men and women, aged 18 to 85 years, has previously answered the 
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SWED-QUAL questionnaire [58]. This was done in 1991. Health status and 
anthropometric data are not known for this Swedish population sample (SPS). The 
SWED-QUAL results of each study participant were matched, and compared with, the 
aggregated results of all SPS individuals of the same age and sex. One participant did 
not complete the SwedQual questionnaire. This explains the difference in the number 
of participants (212 in paper II and 213 in paper III).  
PHYSICAL ACTIVITY AND EXERCISE CAPACITY ASSESSMENT 
Physical activity was self-reported. The study participants were asked to indicate, in a 
questionnaire, an estimate of habitual low, medium and high intensity physical 
activities. The question was: How often do you perform physical activities more than 
30 minutes at a time? Low, medium and high intensity physical activities were 
specified as low = not strenuous (e.g. bowling golf, slow walk, slow bicycle ride, light 
gardening), medium = strenuous but still allowing you to continue a conversation (e.g. 
tennis, dancing, riding, brisk walk, strenuous gardening) and high = strenuous enough 
to cause sweating, increased heart rate and pronounced shortness of breath (e.g. 
aerobics, workout, jogging, fast bicycle ride). Alternative answers were: never, 
irregularly, once a week, twice a week, > 2 times a week. The questionnaire has 
previously been used in the Stockholm Diabetes Prevention Programme [54]. The 
participants were also asked to estimate their physical activity level during the six 
months prior to the study and during study participation using a visual analogue scale 
(VAS) to rank the frequency of physical activity from 0 mm (none) to 100 mm 
(intensive daily activity). The duration and date of each Nordic walking bout were 
recorded in an exercise diary kept by the participants in the exercise group. To compare 
self-reported physical activity with an objective assessment, 25 consecutive participants 
(n=11 from the control group and n=14 from the intervention group) agreed to wear an 
accelerometer (ActiGraph model GT1M; ActiGraph, Pensacola, Florida, USA), in a 
belt around the waist, for seven days from morning to bedtime, shortly after 
randomization [63]. Physical activity was recorded as total activity counts per minute, 
minutes per day of inactivity, low, moderate, or vigorous activity. Peak oxygen uptake 
(peak VO2) was assessed at the time of inclusion and after four months. Exercise tests 
were performed using an ergometer bicycle. The initial work load was set at 50 W and 
was increased by 10 W/min. An ergospirometer was used to measure gas exchange. 
Oxygen uptake (VO2) was calculated breath by breath, and the mean value for the latest 
30 seconds was used. The VO2 at peak exercise (peak VO2) was determined at the point 
of subjective exhaustion.  
SKELETAL MUSCLE GENE EXPRESSION ASSESSMENT 
A total of 112 individuals, with NGT or T2DM, who underwent the exercise 
intervention, provided biopsies from the vastus lateralis of the Quadriceps muscle of 
the thigh before and after 4 months of Nordic walking. They were matched for age 
(61±5 years) and BMI (30±5kg/m2) with NGT (n=79) or T2DM (n=33). The aim of 
this study, paper IV, was to compare the expression of messenger RNA (mRNA) of 
four mitochondrial enzyme proteins involved in the intracellular energy regulation of 
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glucose and fatty acid metabolism. The balance between glucose and fatty acid 
metabolism is determined by a number of genes that regulate the synthesis of enzymes 
that are necessary for the chain reactions leading to the oxidation of glucose and fatty 
acids. Pyruvate Dehydrogenase Kinases (PDKs) is a group of enzymes that reduce the 
rate of carbohydrate oxidation. The PDK isoforms primarily expressed in skeletal 
muscle are PDK2 and PDK4. PDK4 mRNA expression is increased in human skeletal 
muscle during exercise. Malonyl-CoenzymeA Decarboxylase 1 (MCD1) and Carnitine 
Palmitoyltransferase 1b (CPT1b) are both involved in the coordination of fuel balance 
between glucose and fatty acid metabolism during exercise and in metabolic disease. 
CPT1b has been linked to the regulation of insulin sensitivity and exercise has been 
shown to increase the expression of MCD1 in human muscle [64,65]. 
STATISTICS 
Stata statistical software (StataCorp., College Station, TX, USA) was used for all 
statistical analyses in papers I, II and III. In paper IV SPSS version 17.0 (SPSS, 
Chicago, IL, USA) was used. Comparisons were considered statistically significant at 
p<0.05 in papers I–IV.  
Paper I 
A power calculation, based on the assumed differences in HbA1c of 0.8% between the 
control and intervention groups, with SD 1.0, α=0.05 and power=0.8, indicated that 25 
participants would be required in each group. We aimed at including 30 individuals in 
each group, to compensate for participants who might leave the study before it was 
finished. Data are presented as mean±SD or mean (95% CI). Paired t-test was used for 
the analysis of differences within groups and two-sample t-test was used for differences 
between groups.  
Paper II 
A power calculation, based on the assumed differences in SWED-QUAL scales of 0 vs 
5 between the control and intervention groups, with α=0.05 and power=0.8, indicated 
that 63 participants would be required in each group. With the skewed randomization, 
explained above, a power =0.8 would be obtained by 77/54 participants. In the NGT 
group we included 75/53 individuals (= power 0.7957). The study was underpowered 
for IGT (20/14) and T2DM (30/20) participants. Differences within and between 
groups were calculated by non-parametric tests; Wilcoxon’s signed-rank test for within-
group comparisons and Wilcoxon’s rank-sum test for between-group comparisons. 
Therefore, the score for each quality-of-life scale in the SWED-QUAL questionnaire 
was calculated as the median (25th;75th percentile) of the items (questions) included in 
each of the 13 scales. Sex differences between groups were calculated by χ2 test. 
Spearman’s rho was determined for the assessment of correlation. 
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Paper III 
Data are presented as mean±SD. Within-group differences were analysed by paired t-
test and for the analysis of between-group analysis two-sample t-test was used. 
Differences of sex distribution, medication and physical activity levels were analysed 
by χ2 or Fisher’s exact test. Analyses in papers II and III were performed as intention-
to-treat. Follow-up data were missing for 10 participants who left the study after 
inclusion. The principle of last-observation-carried-forward was applied to those 
individuals and baseline data were therefore also included in the statistical analysis as 
follow-up data. 
Paper IV 
Data are presented as mean±SEM and a two-sample t-test was used for the analysis of 
baseline differences in gene expression between the NGT and the T2DM groups. 
Pearson correlations were calculated for baseline measurements of gene and clinical 
parameters. Regression models controlled for covariates (age, sex and BMI) were used 
to examine clinical predictors of gene expression. For the analysis of the fold-change of 
gene expression following exercise intervention, a paired t-test was used. Natural log 
transformation was applied when data were not normally distributed. 
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RESULTS 
STUDY 1, PAPER I 
Baseline characteristics did not differ between the control and the intervention groups. 
Although mean SBP at baseline was markedly higher in the control group than in the 
intervention group, 154.8±18.6 vs 146.9±13.5 mmHg, this difference was not 
statistically significant by 2-sample t-test (p=0.09). Self-reported exercise at baseline 
exceeded 3 × 45 minutes of walking per week, by 15 patients in the control group and 
by 11 in the intervention group. Exercise was increased in the intervention group by 1.2 
(0.7 to 1.7) hours per week and in the control group exercise was increased by 0.2 (–0.6 
to 1.0) hours per week. Data are mean (95% CI). Nine patients in the intervention group 
did not alter their exercise habits. Six of them remained on a low physical activity level 
and three maintained their pre-study level of exercise, which was higher than what was 
prescribed in the study protocol. 
There were no significant changes of parameters reflecting glucose metabolism, i.e. 
HbA1c, fasting plasma glucose or insulin levels. In the intervention group there was a 
tendency towards a decrease in SBP and DBP. In the control group the tendency was 
towards a rise in SBP and DBP. When analysed by paired t-test, HDL and LDL 
cholesterol levels were significantly (and identically) improved in both groups; 0.14 
(0.10 to 0.18) and –0.4 (–0.7 to –0.1) respectively. Data are mean (95% CI).  
Seventeen patients in the intervention group attained 80% or more of the increment 
of physical activity stipulated for the intervention group. In this subgroup SBP, DBP, 
BMI and total plasma cholesterol were significantly improved.  
STUDY 2, PAPER II  
Baseline health-related quality of life, reported by the study cohort of 212 overweight 
or obese individuals with NGT (n=128), IGT (n=34) and T2DM (n=50), was similar to 
or better than an age-and-sex-matched Swedish population sample, for 12 of 13 quality-
of-life scales of the SWED-QUAL questionnaire. The T2DM cohort reported quality-
of-life scores at the same level as the NGT cohort, for all 13 SWED-QUAL scales 
(Wilcoxon’s rank-sum test, statistics not shown). Only 5 individuals in the T2DM 
cohort were newly diagnosed at the time of inclusion in the study. The other 45 had 
been diagnosed prior to participating in this study. Self-reported physical activity, 
assessed by visual analogue scale (VAS), increased significantly in the NGT and 
T2DM intervention groups by 30 (10;40) and 24 (10;40) mm respectively, median 
(25th;75th percentile). Adherence to the Nordic walking study protocol was assessed 
from the walking diaries obtained from 91% of the participants in the intervention 
groups. According to those diaries ≥80% (≥4 h/week) of prescribed Nordic walking 
was reported by 74% of the participants with NGT, 67% of IGT and by 50% of the 
T2DM participants. Hours per week of Nordic walking were 4.7 (4.1;5.2), 4.6 (3.7;6.0), 
and 3.8 (3.1;4.7) for the NGT, IGT, and T2DM groups, respectively. ANOVA did not 
indicate any significant difference between the three groups (p=0.1468). Comparison 
by Wilcoxon’s Rank-Sum test showed a significant difference between NGT and 
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T2DM participants (p=0.0218), whereas comparisons between NGT-IGT and IGT-
T2DM participants showed no significant differences in hours of Nordic walking per 
week (p=0.8702 and 0.1557, respectively). Total counts per minute, recorded by 
accelerometers, were 348 (220;528) for the control group (n=11) and 466 (348;623) for 
the intervention group (n=14), p< 0.001, Wilcoxon rank-sum test. Data are median 
(25th;75th percentile).  
After four months of Nordic walking, quality of sleep and general health perception 
improved significantly in the NGT intervention group, compared with the NGT control 
group; effect size 0.4 and 0.1, respectively. In the T2DM intervention group quality of 
sleep and satisfaction with physical health improved in the intervention group, 
compared with the T2DM control group; effect size 0.5 and 0.7 respectively.  
Pain tended to be more pronounced in the study group as a whole, compared to the 
Swedish population sample, although this difference was not statistically significant. 
After four months pain had not increased in the NGT, IGT or T2DM intervention 
cohorts and there were no reports of musculoskeletal pain that limited Nordic walking. 
BMI improved in the NGT intervention group (p<0.01), compared with the NGT 
control group. Correlation analysis showed no significant relationship between the 
improved quality of sleep and the lowered BMI (Spearman’s rho –0.12). 
STUDY 2, PAPER III  
At baseline the control (n=126) and intervention groups (n=87) differed in some 
respects. The most prominent difference was the low degree of self-reported high-
intensity physical activity in the NGT intervention group, compared with the NGT 
control group (p<0.001). Moreover, lipid regulating statin medication was more 
prevalent in the NGT intervention group (p<0.05) and total plasma cholesterol level 
was slightly lower (p<0.05) in that group, compared with the NGT control group. In the 
T2DM intervention group plasma triglyceride levels were higher than in the T2DM 
control group (p<0.05). Other baseline differences between control and intervention 
groups were not statistically significant.  
The effects of Nordic walking were most pronounced in the NGT intervention 
group, where body weight (–2.0±3.8 kg), BMI (–0.8±1.4 kg/m2) and waist 
circumference (–4.9±4.4 cm), (mean±SD), were significantly improved compared with 
the NGT control group (p<0.01). Self-reported medium and high-intensity physical 
activity were also increased in the NGT exercise group (p<0.001). Self-reported 
physical activity improved less in the IGT and T2DM cohorts, although the increment 
of high-intensity physical activity reached statistical significance in the T2DM 
intervention group (p=0.012).  
The time spent on Nordic walking, reported as hours/week from the diaries kept by 
the intervention groups, did not differ significantly between the NGT (4.7±1.5), IGT 
(4.8±1.8) and T2DM (3.9±1.4) cohorts (p=0.1468 by ANOVA). Among the 25 
participants who agreed to wear an accelerometer for one week, the 14 intervention 
participants were more physically active than the 11 control group participants. Total 
activity counts per minute, total activity counts per day, minutes of vigorous activity 
per day and inactive minutes per day all indicated that the intervention participants 
were more physically active than the control participants (p <0.001, <0.05, <0.005 and 
<0.05, respectively).  
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Exercise capacity, assessed by ergometry cycle tests as power output and peak VO2, 
were significantly improved in the IGT intervention group, compared with the IGT 
control group (p <0.005 and <0.05, respectively). 
HbA1c, HOMA insulin resistance, serum lipids, systolic and diastolic blood 
pressure were unaltered between the NGT, IGT and T2DM exercise and control 
groups. In the T2DM exercise group, however, the 2h post OGTT plasma glucose (–
1.8±2.6 mmol/l), the HbA1c (–0.3±0.6% / –3.3±6.6 mmol/mol), and exercise power 
output improved (7.4±11.5W) in the intra-group analysis by paired t-test (p <0.01, 
<0.05 and <0.05, respectively). 
Adherence to the exercise programme varied within the intervention groups. 
Therefore we performed a separate analysis for the 55 exercise participants who 
reported ≥80% of the prescribed time of Nordic walking in their exercise diaries. In this 
group power output and/or peak VO2 significantly improved for the NGT, IGT and 
T2DM participants, compared with their respective control groups. Improvement of 
body weight, BMI and waist circumference was similar to that of the entire NGT, IGT 
and T2DM exercise groups.
  
Ten individuals left the study before follow-up examination. The motives for 
leaving were personal reasons/lack of time (4), medical reasons (4) and unknown (2). 
Medication was altered for 4 individuals during the study; 2 were started on anti-
hypertensive treatment and 2 had their anti-hypertensive treatment altered. 
STUDY 2, PAPER IV  
At baseline the mRNA expression of PDK4 was increased in the T2DM patients by 
approximately 70%, compared with the NGT participants. The mRNA expressions of 
PDK2 and MCD1 were increased by approximately 50% in the T2DM patients, 
whereas the mRNA expression of CPT1b was similar between T2DM and NGT 
participants.  
The PDK4 gene expression was significantly associated with BMI, even after 
adjustment for age, sex and glucose tolerance.  
After a four-month exercise intervention, PDK4 gene expression was significantly 
increased in the NGT group, but not in the T2DM group. PDK4 expression was 
elevated at baseline in the T2DM cohort, but it did not increase further after the 
exercise intervention. 
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DISCUSSION 
GENERAL COMMENTS 
The strength of our studies is that they were performed in a primary care setting near 
the homes of the patients, where they also receive their regular diabetes care. 
Furthermore, no special equipment was utilized. Therefore the intervention could be 
employed by most patients with type 2 diabetes and our method can be applied to the 
diabetes care programmes of other primary care centres. 
Different levels of physical activity may affect different risk factors for type 2 
diabetes assessed in our studies. The results of study 1 would imply that SBP and DBP 
are improved at a less frequent, or less intensive exercise level, whereas long-term 
effects on glucose metabolism (HbA1c, insulin sensitivity) may require a higher dose 
of exercise (frequency or intensity). As a comparison one study has reported significant 
improvements of HbA1c, SBP, DBP, total cholesterol and triglycerides for type 2 
diabetes patients who increased their exercise by ≥30 minutes of daily walking [37]. 
When motivating the patient with type 2 diabetes to increased physical exercise it may 
be important to assess an array of known risk factors, since not all of them may be 
improved. In addition, it is also necessary to know that they will not get worse by 
exercise. The improvement of one or two risk factors may act as a stimulation to 
maintain the achieved level of exercise and perhaps to increase that level in order to 
improve risk factors not yet improved. Our results suggest that 45 minutes of walking 3 
times per week represents a frequency at which some well-known risk factors are 
favourably changed in type 2 diabetes. However, since we could not observe any long-
term effects on glucose metabolism, the conclusion should probably be that patients 
with T2DM ought to aim for more frequent and intensive exercising than that which 
was applied in study 1.  
Already in 1992 doubts were raised [66] about the feasibility of making patients 
with T2DM adhere to exercise programmes over an extended period of time, pointing 
out the high drop-out rate from a current exercise study of T2DM patients conducted in 
the 1980s [67]. Cardiovascular co-morbidity may also prevent many patients with 
T2DM from participating in more intensive exercise. It has also been demonstrated that 
sedentary patients with T2DM have a lower physical work capacity (VO2max) than 
sedentary control subjects [68,69]. Although VO2max improved in the T2DM group 
after 3 months of regular training it was still lower than that of the untrained sedentary 
control group. This impaired exercise capacity may suggest that patients with T2DM 
are less able to benefit from the effects of physical training than healthy individuals. 
Failing adherence to exercise programmes over time has proved to be an obstacle to 
obtaining long-term effects of physical activity. A ten-year experience of a 
comprehensive life-style modification programme, emphasizing physical training, was 
that after three months only 50% of participants were still enrolled and by the end of 
one year approximately 90% had dropped out [69]. The mode of exercise was aerobics, 
and sessions lasted 40–60 minutes 3–4 times per week. After participating for three 
months, significant improvements were reported in the T2DM cohort for SBP –5 mm, 
BMI –2.2 kg/m2, fasting plasma glucose –2.5 mmol/l, HbA1c –1% and triglycerides –
42 mg/dl (~0.5 mmol/l). 
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The effects of brisk walking or Nordic walking in T2DM patients have been 
described in three recent studies [70-72], two of which continued for four months and 
one for a year. Low compliance was described as a problem in all three studies with 
high drop-out rates, mainly due to musculoskeletal symptoms and lack of motivation. 
HbA1c improved in one study when only participants who attended at least 50% of 
exercise sessions were included in the analysis. In the other two studies HbA1c did not 
improve. Systolic and diastolic blood pressure improved in one, but BMI and plasma 
lipids did not improve in any of the three studies. The overall impression is that brisk 
walking or Nordic walking does not offer a sufficient amount of exercise to 
substantially improve glycaemic control, body weight or the cardiovascular risk factors 
known to be common in T2DM. Moreover, adherence to exercise programmes 
exceeding three months’ duration has been low in most studies, apparently also in 
studies involving rather low-intensity exercise such as walking. 
The parameters recorded in our studies apparently did not show consistent 
improvement between studies and therefore may not be relied upon as motivational 
factors to make diabetes patients become more physically active. Immediate decrement 
of plasma glucose, demonstrated after a bout of exercise, although a short-lived effect, 
may better motivate diabetes patients to exercise on a daily basis.  
Insulin resistance in T2DM causes a shortage of fuel, particularly in skeletal muscle, 
leading to impaired energy production in muscle cells. A mitochondrial gene 
expression that favours the use of FFA, as described in our paper IV, may be an 
indication of this metabolic derangement. It may also imply that patients with T2DM 
cannot benefit from the health effects of exercise to the same extent as people who do 
not have T2DM. Since energy metabolism is less deranged in the IGT state it seems 
probable that the health effects of exercise are more pronounced in this pre-diabetic 
state than in established T2DM.  
Therefore, realistic expectations of exercise effects in T2DM patients should 
possibly be lower than for people free of T2DM, and individually adjusted. Several 
studies [73-75] have shown that people who are physically active and physically fit live 
longer, and this holds true for people with T2DM as well. This ought to be a good 
incentive for staying physically active, to people with or without T2DM. 
HRQoL has seldom been addressed in research concerning physical activity in 
diabetes care. Aspects related to quality of life may play an important role for the 
feasibility of implementing regular habits of exercise in diabetes care. The SWED-
QUAL results from a Swedish population sample were obtained in 1995. The 
comparison of HRQoL between the SPS and the participants in our study 2 should 
therefore be interpreted with some caution. The general perception of quality of life 
may have changed over time, and this could possibly be one reason for the high level of 
reported HRQoL in paper III. There were no indications, however, that the modest 
increase of physical activity implied in our studies impaired the HRQoL of the 
participating patients. Individuals with known angina pectoris were excluded from 
participation. This may account for the lack of adverse reactions to exercise in this 
study. It may be argued that for each individual there is a level of exercise, above which 
the exercise activity per se may be detrimental to quality of life. Our study indicates 
that positive effects on risk factors may occur at levels of exercise that do not 
negatively affect the patients’ quality of life. A good clinical strategy may therefore be 
to encourage stepwise increases of physical exercise to patients with type 2 diabetes, 
supporting modes and amounts of exercise that are feasible to the individual patient. 
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Quality of sleep, which improved in study 2, appears to be a sensitive marker of 
well-being, and insomnia has been identified as one psychological stress factor that 
contributes to an increased risk of developing pre-diabetes [54], diabetes [76] and 
hypertension [77]. Participating in physical activity at least once a week, or taking a 
brisk walk daily, has been reported to reduce the risk of sleep disorders [78]. A meta-
analytic review has, however, reported contradictory results concerning the relationship 
between sleep physiology and physical activity [79]. 
Limitations to our studies are the small number of patients included and the short 
period of intervention. Furthermore, the intensity of exercise was not well defined. It 
may be preferable to specify an exercise intensity that brings about a certain percentage 
of maximum heart rate. These limitations render our conclusions uncertain. On the 
other hand, controlling the intensity of exercise would require the supervision of 
exercise sessions. This would diminish the desired effect of “real life” circumstances to 
our studies. 
Assessing physical activity 
To assess the amount of physical activity performed by the individual is not an easy 
task, and assessments can seldom be completely accurate. The registration of physical 
activity on a 24-hour basis can be done for a limited period of time using accelero-
meters. Bouts of exercise can be registered with respect to duration, work load and 
heart rate. This method does not account for other modes of physical activity than 
exercise training, such as transportation or occupational and home activities, and 
therefore offers a limited picture of the individual’s energy expenditure. Self-reported 
physical activity can be obtained with the use of various questionnaires and may 
involve other aspects of physical activity than exercise training. The Compendium of 
Physical Activities [80] is a tool that helps in the classification of self-reported physical 
activities, where each activity has been assigned a metabolic equivalent intensity level 
(MET). One MET unit is the resting metabolic rate obtained in a sitting position. By 
multiplying the MET level and duration of various self-reported modes of physical 
activity it is possible to estimate individual physical activity in terms of MET hours per 
week. This method does not require any equipment for registration, but the reliability of 
the results is limited by recall bias. Unluckily enough, we also found that the results 
from the physical activity questionnaire, physical activity VAS estimation and walking 
diaries were not precise enough to be converted to MET hours per week. 
Effect of physical activity – hard end-points or surrogate variables? 
The effect of physical activity may be assessed in various ways. In our studies we have 
focused mainly on variables that are commonly measured in clinical practice, generally 
known as “risk factors” or “surrogate variables”. Body weight, BMI, waist 
circumference, level of physical activity, blood pressure and levels of blood lipids and 
blood glucose are such risk factors, commonly included when estimating a 
cardiovascular risk profile in primary health care. It is advantageous to assess clinically 
adequate risk factors that may improve within a short period of time as a result of 
intervention. Such improvements are encouraging to the individual. 
Regular walking 150 minutes per week prevents, or at least delays, the development 
of IGT to T2DM [6,8]. Furthermore, walking ≥1 mile per day has been shown to 
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decrease the risk of cardiovascular mortality in male and female patients with T2DM 
aged 50–90 years [11]. Frequent as well as occasional self-reported physical activity 
has been shown to correlate to reduced all-cause mortality in male and female 
individuals aged ≥65, with or without T2DM [81]. The increase of physical activity 
levels in 50-year-old men over a period of 10 years reduced total mortality, compared 
with men who maintained a low level of physical activity [9]. To focus on avoiding 
more definite end-points such as premature death or the development of T2DM or 
cardiovascular disease may not be as efficient in promoting lifestyle changes as the 
demonstration of improved clinical risk factors after a limited period of lifestyle 
intervention. 
Better effects on risk factors if they are more pronounced at baseline?  
In our studies the effects of exercise intervention on most of the clinical risk factors 
under study have been mild or non-existent. The exception to this is the improvement 
of body weight, BMI, waist circumference and exercise capacity in study 2. BMI, SBP 
and DBP tended to improve in study 1, and this improvement reached statistical 
significance in the subgroup of seventeen intervention participants who achieved 80% 
or more of the physical activity intended in study 1. Baseline blood pressure levels in 
study 1 were higher than in study 2. At baseline SBP in study 1 was 150.8 ±16.6 and in 
the study 2 cohort 139.7±13.8 (p<0.001). DBP was 85.1±7.3 and 84.4±8.2 respectively, 
p=0.58 (mean±SD). The higher baseline SBP in study 1 may explain the more 
favourable effects on blood pressure in that study. 
A meta-analysis of clinical trials has demonstrated that a higher baseline level of 
HbA1c results in a more pronounced decline following glucose-lowering medication 
than if the HbA1c was lower at baseline [82]. This supports an intuitive assumption that 
clinical parameters that are not being well controlled are more likely to improve after 
appropriate intervention than parameters that are well controlled before intervention.  
MUSCLE BIOPSY FINDINGS – A CHALLENGE FOR INTERPRETATION 
Previous studies have shown that a reduction of MCD expression enhances glucose and 
reduces lipid metabolism in human muscle cells [83]. The increased MCD1 expression 
reported in paper IV may thus play a role in reducing muscle glucose utilization in 
individuals with impaired glucose tolerance/T2DM. 
The elevated PDK4 mRNA expression noted at baseline in the T2DM cohort and 
following an exercise intervention in the NGT cohort is enigmatic. Elevated PDK4 
expression has been associated in other studies with high levels of circulating lipids, in 
rats, and hyperinsulinaemia has been shown to suppress the PDK4 expression [84,85]. 
The elevated PDK4 expression at baseline in the T2DM cohort may reflect a state of 
insulin resistance in that group of participants, providing for the switch to lipid 
oxidation in order to secure an adequate cellular supply of fuel for energy production. 
This could be a result of impaired glucose utilization in T2DM. After a period of 
Nordic walking, gene expression of PDK4 increased in the NGT cohort but not in the 
T2DM group. This may indicate that individuals with NGT can improve their ability to 
utilize FFAs for fuel by physical activity, whereas people with T2DM cannot benefit to 
the same extent from the metabolic effect of physical exercise. 
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Current recommendations of physical activity 
A systematic review and meta-analysis of 47 randomized controlled trials, including 
8538 patients has recently presented data from current research on the effects of 
exercise on glycaemic control in T2DM [86]. The conclusion of this meta-analysis is 
that structured exercise training that consists of aerobic exercise, resistance training, or 
a combination of both, is associated with the reduction of HbA1c in patients with 
T2DM. Furthermore, exercise duration of more than 150 minutes per week was 
associated with greater HbA1c declines than that of 150 minutes or less per week. The 
intervention effect was more pronounced among individuals with HbA1c greater than 
7% at baseline (NGSP standard, comparable to 53 mmol/mol IFCC standard), than 
among those with HbA1c levels less than 7%. More intensive exercise was, however, 
not associated with greater HbA1c declines. The American Diabetes Association 
supports a recommendation of 150 minutes per week of accumulated moderate physical 
activity (50–70% of maximum heart rate) for patients with type 2 diabetes. This 
recommendation is believed to be the most beneficial in the prevention of, and in the 
early stages of overt type 2 diabetes [87]. Moreover, resistance training 3 times per 
week, in addition to aerobic exercise, is recommended, in the absence of 
contraindications. For patients with type 2 diabetes, >65 years of age, the 
recommendation is to stay as physically active as possible, according to individual 
abilities [87]. The effect of exercise alone, without dietary restrictions or behaviour 
modification, on body weight is modest and commonly amounts to a weight loss of 
~2kg [88]. Some authors suggest that 45 to 60 minutes of daily moderate-intensity 
activity is required to prevent the transition to overweight or obesity [89]. The effects of 
exercise on blood pressure and lipids have also been reported to be relatively modest 
[88]. For safety reasons it has been recommended that patients with type 2 diabetes 
undergo a medical examination to evaluate the risk of cardiovascular complications, 
before increasing the level of physical activity. Such testing is no longer considered 
necessary for moderate-intensity exercise such as walking. The recommendation to 
avoid physical activity in case of hyperglycaemia is justified in type 1 diabetes, but in 
adequately hydrated patients with type 2 diabetes who feel well it is not considered 
necessary to postpone exercise because of hyperglycaemia alone [88].  
33 
CONCLUSIONS  
 
Physical exercise in the form of brisk or Nordic walking is feasible for most people 
with overweight, normal or impaired glucose tolerance, or type 2 diabetes, if not 
physically disabled.  
 
Study 1, paper I  
After three 45-minute walks per week SBP and DBP tended to improve in the 
intervention group. For the participants who performed ≥80% of prescribed brisk 
walking during four months the improvement of blood pressures, BMI, LDL, HDL and 
total cholesterol reached statistical significance. However, parameters reflecting 
glucose metabolism did not improve.  
Study 2, paper II  
Quality of sleep improved in the NGT group following four months of Nordic walking, 
five hours per week. BMI reduction did not account for this improvement. Nordic 
walking can be introduced in a primary health care setting as a low-cost mode of 
exercise that promotes weight loss and improved health satisfaction.  
Study 2, paper III  
Nordic walking improved anthropometric measurements and exercise capacity. 
However, unsupervised Nordic walking may not provide sufficient exercise intensity to 
achieve ultimate health-promoting benefits on the cardiovascular parameters assessed 
in this study, particularly for those with disturbed glucose regulation. 
The intervention effects of Nordic walking were the most pronounced in the NGT 
group, where body weight, BMI and waist circumference were significantly improved. 
Self-reported physical activity improved less in the IGT and T2DM cohorts, although 
the increment of self-reported high-intensity physical activity reached statistical 
significance in the T2DM intervention group.  
Performing ≥80% of the time of Nordic walking prescribed in this study, 
significantly improved exercise power output and/or peak VO2 for the NGT, IGT and 
T2DM participants, assessed by ergometry cycle tests. 
Study 2, paper IV  
The mRNA expression of PDK4, PDK2 and MCD1 was up-regulated at baseline in 
skeletal muscle of the T2DM cohort. No further elevation occurred for any of the three 
enzymes after an exercise intervention. The lack of effects on PDK4 expression 
following exercise intervention implies a possible resistance to the appropriate adaptive 
responses to exercise in skeletal muscle associated with insulin resistance. In the NGT 
cohort, however, the PDK4 expression was significantly elevated following the 
exercise intervention. This may reflect an increased capacity for lipid oxidation in a 
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state of increased total energy demand. Skeletal muscle is known to rely on lipid 
oxidation, particularly when exposed to low-intensity exercise [19,23,90]. 
FUTURE PERSPECTIVES 
According to the official survey of living conditions, conducted on a regular basis by 
Statistics Sweden [91], the prevalence of overweight (BMI ≥25) and obesity (BMI ≥30) 
in Sweden has increased over the past 30 years for men and women aged 16–84 years. 
In 1980–81 overweight was reported by 31% of men and 22% of women, and 5% of 
men and women were obese. The corresponding figures for 2010–11 were 42/28% for 
overweight and 12/11% for obesity. It is intriguing to note that for the same period of 
time self-reported physical activity has increased among Swedish men and women aged 
16–84 years [91]. In 1980–81 exercise ≥1 time per week was reported by 47% males 
and by 43% females. Exercise ≥2 times per week was reported by 30% males and 24% 
females. Corresponding figures for 2010–11 were 72/76% for exercise ≥1 time per 
week and 60/66 for exercise ≥2 times per week. These results may indicate that 
sedentary activities are so predominant in many people’s daily lives that negative health 
effects, such as overweight/obesity, cannot be counterbalanced by bouts of exercise 
performed on one or more occasions per week. Prolonged sitting has been shown to be 
a significant risk factor for all-cause mortality independent of age, sex, BMI, physical 
activity levels, and the presence or absence of cardiovascular disease or diabetes [92]. 
The accumulated daily amount of physical activity, measured by an accelerometer, has 
been reported to be a major determinant of insulin sensitivity in healthy, normal-weight 
men and women. The effect was independent of time spent sedentary, in light-intensity 
activity or in bouts of moderate or vigorous activity [93]. According to another study, 
the number of daily interruptions of sedentary time correlate to beneficial effects on 
waist circumference, BMI, triglycerides and 2-h plasma glucose, in overweight healthy 
men and women. The beneficial effects were independent of total sedentary time or 
time spent in moderate-to-vigorous physical activity [94]. 
It is a challenge to providers of primary health care to develop methods and 
strategies that help patients with type 2 diabetes, and persons at risk of developing that 
disease, to incorporate regular physical activities in daily life. Such strategies ought to 
involve not only “exercise” activities but also aspects of habitual physical activities in 
everyday life. Transportation to and from work, household activities, shopping and 
gardening are activities that can be performed in more or less physically demanding 
ways. Health care providers ought to provide not only objective information on the 
health benefits of regular physical activities but should also be able to refer the patients 
to suitable exercise activities offered in the community. The organizing of walking 
groups could even be included in the services offered by a primary care centre. It is not 
time-consuming and need not cause any extra expenses for the patients or the primary 
care provider. Exercise on prescription (EoP) has been used in primary health care in 
several European countries and in the USA with the aim of providing support to 
patients for increased physical activity. The aim of EoP is usually to promote activities 
that are more physically demanding than walking. Two systematic reviews report that 
EoP appears to have small effects on increasing physical activity in sedentary people 
[95] but increases physical activity levels in older adults who are already slightly active 
[96]. In one review, physical activity was increased in half of the studies and EoP 
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schemes were found to be an acceptable tool for motivating general practitioners to 
promote physical activity [97]. One Swedish study has reported increased physical 
exercise and improved quality of life following a period of EoP [98].  
The beneficial effects of regular physical exercise in the prevention and treatment of 
type 2 diabetes and the detrimental effects of a sedentary lifestyle are indisputable. It is 
therefore important to convey results from research on everyday exercise activities to 
the public as well as to primary health care providers. Such basic knowledge is crucial 
to the feasibility of implementing lifestyle alterations in patients with IGT and T2DM. 
This may be one prerequisite for avoiding future cardiovascular complications that are 
a threat in T2DM.  
However, further studies are needed to establish how different modes, intensities 
and frequencies of exercise affect cardiovascular risk factors and HRQoL in type 2 
diabetes. It is also important to widen our understanding of the physiological 
mechanisms involved in glucose metabolism and insulin resistance with relation to 
physical exercise. Although the connection between a sedentary way of life and the 
development of insulin resistance is well established, the biochemical mechanisms 
involved are not well understood. We do not know whether different modes of exercise 
are more or less efficient in enhancing insulin sensitivity in skeletal muscle. 
Furthermore, it is not clear whether or not the responsiveness to exercise differs 
between individuals. Studies on the intracellular proteins in skeletal muscle, involved in 
insulin signalling and glucose metabolism as well as FFA metabolism, may add to our 
understanding of the role of regular physical exercise in the prevention and treatment of 
type 2 diabetes. 
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SVENSK SAMMANFATTNING/SWEDISH SUMMARY 
Bakgrund och mål 
Typ 2-diabetes (T2DM) är en sjukdom som är starkt kopplad till en ökad risk för 
allvarliga blodkärlskomplikationer i hjärta, hjärna och ett flertal andra organ i 
människokroppen. Risken för att utveckla T2DM är relaterad till individens genetiska 
arv, en låg grad av fysisk aktivitet, övervikt och socioekonomiska faktorer.  
Mitt mål har varit att studera effekterna av ökad fysisk aktivitet på kliniska 
riskfaktorer för hjärt-/kärlsjukdom, hälsorelaterad livskvalitet och på det genetiska 
uttrycket för mitokondriella enzymer som är centrala i glukos- och fettmetabolismen, 
hos överviktiga personer med T2DM, nedsatt eller normal glukostolerans.  
Metod 
Två olika motionsstudier genomfördes. I båda studierna omfattade studieperioden fyra 
månader.  
I studie 1, som publicerades i artikel I, inkluderades endast personer med T2DM; 27 
i interventionsgruppen och 31 i kontrollgruppen. De var 60,0±6,5 år med diabetes 
sedan 6,0±5,5 år tillbaka, kroppsmasseindex (BMI) 32,0±5,3 kg/m2 och 
långtidssockervärde (HbA1c, Mono S standard) 6,3±0,9 %. Angivna mätvärden är 
medelvärde±SD. Motionsgruppen rekryterades från en vårdcentral medan 
kontrollgruppen rekryterades från en annan, näraliggande, vårdcentral. Denna studie 
var alltså inte randomiserad. Motionsgruppen instruerades att öka sin fysiska aktivitet 
med 45 minuter rask promenad tre dagar per vecka, medan kontrollgruppen 
instruerades att fortsätta sitt dagliga liv som vanligt. Vid studiestart och efter fyra 
månader mättes systoliskt och diastoliskt blodtryck, BMI och åldersjusterad fysisk 
arbetsförmåga. Samtidigt mättes blodkoncentration för glukos, insulin, HbA1c och 
blodfetter, och insulinkänsligheten beräknades.  
I studie 2, som har legat till grund för artiklarna II, III och IV, inkluderades totalt 
213 överviktiga personer som inte hade några fysiska eller medicinska 
funktionsnedsättningar, i åldern 60±5,3 år, med BMI 30,2±3,8 kg/m2. Motionsgruppen 
instruerades att öka sin fysiska aktivitet med fem timmars stavgång per vecka, medan 
kontrollgruppen instruerades att fortsätta sitt dagliga liv som vanligt. Ett 
glukostoleranstest (s.k. sockerbelastning) vid studiestart möjliggjorde uppdelningen av 
deltagarna i personer med normal glukostolerans (NGT), nedsatt glukostolerans (IGT) 
eller typ 2-diabetes (T2DM). Deltagarna lottades sedan till en kontrollgrupp (n=126), 
eller till en motionsgrupp (n= 87). Mätningar av kroppsmått, blodtryck och 
blodkemiska variabler utfördes vid studiestart och efter fyra månader. Vid dessa båda 
tillfällen besvarade deltagarna även ett frågeformulär med frågor om hälsorelaterad 
livskvalitet (SWED-QUAL) och konditionstest med mätning av 
syreupptagningsförmåga genomfördes. De deltagare som accepterade detta fick även 
lämna ett muskelvävnadsprov i form av en muskelbiopsi från lårmuskeln vid studiestart 
och efter fyra månader. Muskelprovet analyserades sedan för uttrycket av ett antal 
mitokondriella gener, som reglerar syntesen av enzymer inblandade i cellernas glukos- 
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och fettförbränning. Deltagarna i motionsgruppen ombads även att föra en dagbok över 
sina stavgångspromenader.  
Resultat 
I studie 1 visade intention-to-treat-analysen ingen signifikant förbättring av kroppsmått, 
fysisk kondition, glukosmetabolism, blodfettsnivåer eller blodtryck. De 17 deltagare i 
motionsgruppen som uppnådde 80 % eller mer av föreskriven ökning av motionsgraden 
förbättrade däremot signifikant BMI, systoliskt/diastoliskt blodtryck och total 
kolesterolnivå i blodet.  
I studie 2 ökade den självrapporterade fysiska aktiviteten för deltagare med NGT, 
IGT och T2DM i motionsgruppen. Hälsorelaterad livskvalitet vid studiestart var lika 
god som, eller bättre än ett ålders- och könsmatchat svenskt befolkningsurval, för 12 av 
de 13 skalorna som ingår i SWED-QUAL. Sömnkvaliteten förbättrades för 
motionsgruppens deltagare med NGT efter fyra månader med stavgång. I denna grupp 
förbättrades även kroppsvikt, BMI och midjeomfång, och i motionsgruppen med IGT 
förbättrades den fysiska konditionen. Smärta från rörelseapparaten, relaterat till 
stavgångsaktiviteten, rapporterades i liten eller ingen omfattning. De deltagare i 
motionsgruppen som uppnådde 80 % eller mer av föreskriven stavgång förbättrade sin 
fysiska kondition såväl i NGT- som i IGT- och T2DM-gruppen.  
Muskelvävnadsprov från 79 män med NGT och 33 män med T2DM, alla i 
motionsgruppen, analyserades för ett antal mitokondriella gener, som kodar för 
syntesen av enzymer som spelar en viktig roll för förbränningen av glukos respektive 
fria fettsyror i muskelcellernas mitokondrier. Vid studiestart var uttrycket för tre 
mitokondriella gener, mätt som messengerRNA (mRNA), ökade i T2DM-gruppen. I 
NGT-gruppen ökade PDK4-uttrycket efter motionsperioden, men inte i T2DM-
gruppen. 
Slutsatser 
Regelbundna promenader 45 minuter, tre gånger per vecka under fyra månader, 
förefaller inte medföra en tillräcklig mängd motion för att påverka de kliniska 
parametrar som vi har studerat. Genom att öka motionsgraden till stavgång fem timmar 
per vecka kunde vi visa att kroppsvikt, BMI, midjeomfång och sömnkvalitet 
förbättrades i NGT-gruppen och att den fysiska konditionen förbättrades i IGT-
gruppen. Stavgång utgör möjligen en miniminivå av motion som krävs för att förbättra 
kardiovaskulära riskfaktorer och mitokondriella genuttryck med bibehållen livskvalitet. 
Promenader och stavgång kan rekommenderas i primärvård som en säker introduktion 
till regelbunden motion till låg kostnad, till personer med T2DM eller förstadierna till 
den sjukdomen. Genuttryck för enzymer som är involverade i glukos- och 
fettförbränning, särskilt enzymet PDK4, var ökat i gruppen med T2DM, men ej i NGT-
gruppen, vid studiestart. Efter en period av regelbunden stavgång ökade uttrycket för 
PDK4 i NGT-gruppen men inte i T2DM-gruppen. Dessa resultat kan vara ett uttryck 
för att personer med T2DM har en något förhöjd förbränning av fria fettsyror, som en 
kompensation för den försämrade glukosförbränningen som utgör ett grundproblem vid 
T2DM. Å andra sidan kunde vi notera tecken till förbättrad fettförbränning i NGT-
gruppen, i form av ökat PDK4-uttryck efter en period av stavgång. Detta skulle kunna 
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vara ett tecken på att personer med T2DM inte kan tillgodogöra sig de positiva 
metabola effekterna av motion, i samma utsträckning som personer med NGT. 
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APPENDICES 
Errata  
Paper I – results section – “3 min × 45 min increment” should be “3 × 45 min 
increment”. 
 
Paper III – Table 1 – Results for LDL cholesterol have by mistake been inserted in the 
line for HDL cholesterol and vice versa. 
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Abstract
In order to assess the effects of regular walking on metabolic control and cardiovascular risk factors in type 2 diabetes 26
patients from one primary care clinic, aged 60.0  7.3 years, participated in a walking program during 4 months. Prescribed
exercise was walking for 45–60 min three times weekly. A control group of 26 patients from a neighboring primary care clinic,
aged 59.3  6.2 years, received no exercise instructions. Thus, randomization was not performed.
There were no improvements of blood pressure, body mass index, physical fitness, glycated hemoglobin A1c, fasting plasma
glucose or insulin by intention-to-treat analysis. Seventeen patients in the intervention group increased their physical activity
and improved systolic blood pressure; 7.6 mmHg (15 to 0.2), diastolic blood pressure; 4.3 mmHg (7.4 to 1.2), body
mass index;0.6 kg/m2 (1.1 to0.1) and total plasma cholesterol;0.6 mmol/l (0.9 to0.3), (mean difference, with 95%
CI). We could observe no effects on glucose metabolism in either group.
Our results suggest that an increase of regular physical activity equivalent to 45 min of walking 3 days/week may suffice to
improve systolic and diastolic blood pressure, lipid metabolism and BMI in patients with type 2 diabetes.
# 2005 Elsevier Ireland Ltd. All rights reserved.
Keywords: Type 2 diabetes; Exercise; Risk factors
1. Introduction
Cardiovascular morbidity is the major contributory
factor to mortality in type 2 diabetes. In the United
Kingdom Prospective Diabetes Study (UKPDS) sys-
tolic hypertension, dyslipidaemia and hyperglycaemia
were significantly associated with coronary artery
disease [1] and pharmacological treatment of hyperten-
sion was demonstrated to reduce cardiovascular
mortality and morbidity [2]. Furthermore, UKPDS
results show that glycaemic control is more crucial to
the risk of developing micro vascular complications
of type 2 diabetes, i.e. retinopathy and nephropathy,
than macro vascular complications, i.e. stroke and
coronary heart disease [3]. A subgroup analysis of the
Scandinavian Simvastatin Survival Study (4S) suggests
www.elsevier.com/locate/diabres
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that the improvement of blood lipid levels was
beneficial also to patients with type 2 diabetes, with
respect to coronary heart events [4].
Impaired insulin sensitivity is a central metabolic
disturbance in type 2 diabetes with its strongest
expression in skeletal muscle. Physical exercise is
known to enhance insulin sensitivity and is therefore
regarded as a cornerstone in the management of type 2
diabetes [5].
A meta-analysis of 14 controlled trials of physical
exercise concluded that post-intervention HbA1c levels
were lower in the exercise groups compared with the
control groups [6]. Other studies have indicated that
regular walking [7] or more strenuous exercise
programs [8] are beneficial to insulin sensitivity in
type 2 diabetes. Regular exercise, combined with
dietary restrictions, has also been shown to prevent the
development of impaired glucose tolerance into overt
type 2 diabetes [9,10]. Improved glycaemic control,
blood pressure, cholesterol levels and body weight have
been demonstrated in patients with type 2 diabetes after
a lifestyle modification program [11].
Several authors have reported discouraging diffi-
culties in implementing long-term exercise programs
for patients with type 2 diabetes 60 years or older [12–
14]. Many patients are unaccustomed to exercising
[15] and attempts at introducing habits of regular
physical activities may also be limited by other co-
existing ailments. Contrary to this a high attendance to
a long-term exercise program was observed in
younger persons with type 2 diabetes or impaired
glucose tolerance [16].
Current research thus indicates that physical
exercise is associated with improved glycaemic
control, blood pressure and blood lipid levels in type
2 diabetes, as well as a reduced risk of developing this
disease in persons with impaired glucose tolerance.
In Sweden most patients with type 2 diabetes are
cared for in primary health care and one central aspect
of diabetes care ought to concern matters of lifestyle.
There is a need for more detailed knowledge of the
effects of various lifestyle interventions to be utilized in
individual counseling and goal setting in diabetes care.
The aim of this study was to describe the effects on
metabolic control and cardiovascular risk factors in
type 2 diabetes after a period of a low intensity
exercise program feasible to most patients and to the
resources of a primary health care center.
2. Materials and methods
2.1. Patients
Patients with type 2 diabetes were enrolled from
two different primary care practices in two well-
defined suburban communities outside Stockholm,
Sweden. Exclusion criteria were severe angina
pectoris or other severe disability and insulin treat-
ment. Public meetings, advertised in the local press,
were arranged in the two communities and attendants
were invited to participate. In addition, 67 patients
with type 2 diabetes were invited to participate when
visiting their physician and 100 by a personal letter of
invitation.
Twenty-seven patients consented to participate in
the intervention group and 31 in the control group.
One patient in each group declined further participa-
tion shortly after inclusion in the study. Four patients
in the control group were lost to follow-up despite
repeated reminders. Thus, the intervention group and
the control group both consisted of 26 patients.
We chose to invite the patients to the two groups
from different communities in order to diminish the
possibility that the control group patients would start
exercising as they learned about the activities in the
intervention group. This was therefore not a rando-
mized study.
2.2. Study design
The patients in the intervention group were
instructed to increase their exercise by 45 min of
brisk walking, three times weekly, during 4 months.
We expected this to be achievable to most patients.
Four months was considered to be a sufficient period
to allow for changes of the parameters under study.
Walking groups were provided four times per week
and the patients were asked to register every walk in
a diary, whether they were taken in a supervised
group or individually. No recommendations were
given concerning changes of dietary habits and
medication remained unaltered in both groups. The
patients in the control group were informed that their
results were to be used as reference values for
diabetes patients over a period of 4 months when no
alterations of life style or medication were under-
taken.
T. Fritz et al. / Diabetes Research and Clinical Practice 71 (2006) 21–2722
2.3. Methods
At the time of inclusion and after 4 months resting
systolic (SBP) and diastolic (DBP) blood pressure in
the supine position and body mass index (BMI) were
assessed. Since the patients were examined at two
different primary care units different blood pressure
tonometers were used (Speidel and KellerTM). There
were no differences in the blood pressures recorded
with the four different tonometers that were used,
when tested on the same patient for control.
Blood samples, obtained in the fasting state were
analyzed for plasma glucose, insulin, glycated
hemoglobin (HbA1c), and lipid levels (total choles-
terol, HDL and LDL cholesterol and triglycerides).
According to Swedish national diabetes guidelines
HbA1c < 6.5% is regarded as good control.
Insulin resistance was obtained as HOMA2-IR
(Homeostasis Model Assessment) from fasting serum
insulin and plasma glucose levels by the use of the
computerized HOMA calculator as described by
Wallace et al. [17]. Serum insulin levels were analyzed
at a central hospital laboratory using the Auto
DELFIA method (Perkin-ElmerTM).
Blood samples and measurements of other vari-
ables in this study were obtained within 24–48 h after
the last exercise walk.
Age adjusted physical fitness was determined by
bicycle ergometry as a submaximal exercise test. The
patients performed six minutes of cycling at a
resistance (50–150 W) that resulted in a steady heart
rate. The patient’s heart rate, sex and age were used in
the A˚strand nomogram to calculate the predicted
maximum oxygen uptake (VO2 max). A Monark 839E
ergometer cycle was used for the exercise tests
(MONARK EXERCISE ABTM).
The patients answered a questionnaire that focused
on daily physical activity. The questionnaires and
walking diaries made it possible to identify those
individuals in the intervention group who did increase
their actual level of exercise.
2.4. Statistics
Paired t-tests were used to analyze differences
within the intervention group and the control group,
respectively. For analysis of differences between
groups two-sided t-tests were used.
The ethics committee of Karolinska Institutet,
Stockholm, approved this study.
3. Results
Baseline characteristics and results after 4 months
are shown in Table 1. The exercise group increased their
total amount of weekly exercise according to walking
diaries and exercise questionnaires. However, only 17
patients attained 80% or more of the stipulated
3 min  45 min increment. The predominant mode of
exercise reported was walking. Aerobics, swimming,
cycling, gardening, golfing and weight lifting were
activities reported by few patients in each group. At
baseline 11 patients in the intervention group and 15 in
the control group reported habitual exercise exceeding
3  45 min of walking.
There were no significant effects on parameters
reflecting glucose metabolism, i.e. HbA1c, plasma
glucose and plasma insulin levels. HDL and LDL
cholesterol levels were improved in both groups. In the
intervention group there was a tendency towards a
decrease in systolic and diastolic blood pressure. In the
control group the tendency was towards a rise in systolic
as well as diastolic blood pressure. Physical fitness
when measured as predicted VO2 max was average to
low in both groups and did not improve during the study.
In a separate analysis of the 17 patients in the
exercise group that achieved 80% or more of the
prescribed increment of exercise systolic and diastolic
blood pressure, BMI and total plasma cholesterol were
significantly reduced.
Nine patients in the intervention group did not alter
their exercise habits. Six of them remained on a low
level of physical activity and three maintained their
previous level of exercise, which was higher than what
was stipulated for the study.
A number of patients experienced ailments that
limited their participation in physical activities to
some degree. In the intervention group 12/26 and in
the control group 9/26 patients reported such physical
obstacles in the physical activity questionnaire.
4. Discussion
The main results of this study indicate that brisk
walking for 45 min 3 days/week may not provide a
T. Fritz et al. / Diabetes Research and Clinical Practice 71 (2006) 21–27 23
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sufficient increase of physical activity to improve the
degree of glycaemic control, lipid homeostasis or
blood pressure in patients with type 2 diabetes.
Various factors in our study might account for the
absence of improved glycaemic control. The degree of
physical activity obtained by the patients may have
been insufficient. Our patients were in comparatively
good glycaemic control when included in the study.
This implies that the participating patients might have
been a highly motivated group. Other investigators
have demonstrated that diabetes patients with higher
HbA1c levels respond with a more pronounced
decrease in this respect following regular exercise
[11]. With increasing age the glucose metabolism may
react less favourably to physical activity. This may
account for the lack of effect on glucose metabolism in
our study. Furthermore, the number of patients in our
study may have been too small to detect minor effects
on glucose metabolic control in patients who already
had a relatively good metabolic control.
A comparison of our results to those of another
study comprising a similar number of patients with
comparable degree of blood glucose control may be
justified. Yamanouchi et al. [7] studied two groups of
patients with type 2 diabetes, aged 23–59 years. A
‘‘diet and exercise’’ group (DE) walked 13.5 km
daily and a ‘‘diet only’’ group (D) walked 3.2 km
daily during a 6–8 weeks period of hospitalization,
according to pedometer readings. In the DE group
(n = 14) fasting blood glucose improved (6.1–
5.2 mmol/l) as well as insulin sensitivity (euglycaemic
insulin clamp). In the D group (n = 10) fasting blood
glucose improved to a similar degree (5.9–5.1 mmol/l)
whereas insulin sensitivity was not significantly
altered. The dietary restrictions (reduction of daily
caloric intake by 1000 kcal from the patient’s ordinary
intake) may explain the improved glycaemic control
of both groups and the exercise may explain the
improved insulin sensitivity of the DE group. The
authors do not specify the actual increase of walking in
the DE group but a reasonable assumption is that it
amounted to approximately 10.3 km daily, i.e. the
difference between the two groups. This comparison
implies that the relatively small amount of exercise,
rather than the small number of patients or their degree
of glycaemic control, accounts for the absence of
effects on glycaemic variables in our study. It deserves
mention that the patients studied by Yamanouchi et al.
were hospitalized during the study. The amount of
walking applied in our study may better reflect the
amount of exercise feasible in everyday life and
especially in an elderly diabetes population.
Few studies have described the effects of exercise
in type 2 diabetes patients over 55 years of age. Zierath
and Wallberg-Henriksson conclude in a review article
that there is ‘‘a difference in the metabolic response to
regular exercise between younger and older type II
diabetic patients . . . none of the older patient groups
(57–61 years) respond to exercise training with
improved HbA1c levels.’’ [18]
The absence of metabolic response to exercise in
elderly type 2 diabetes patients may be due to
concomitant ailments that prevent more vigorous
exercise. If an age-dependant ‘‘exercise resistance
factor’’ should exist, this would diminish the value of
recommending exercise to elderly patients. At the
same time it seems likely that such an age-dependant
decrement of response to exercise would be subject to
individual variations.
The age of the patients in this study is well
representative of the age of diabetes patients listed to
Swedish primary health care. According to current
data from the National Diabetes Registry of Sweden
23% of the 65,000 patients registered in primary
health care are aged 30–59 years and 77% are 60 years
or older.
VO2 max did not change in any of our groups. Walker
et al. have reported improved fitness, expressed as
estimated VO2 max, following a period of walking for
1 h/day on 5 days weekly during 12 weeks, in postmeno-
pausal women with and without type 2 diabetes [19].
The amount of exercise, in our study, may have been
insufficient for increasing respiratory fitness. The
exercise levels required to improve glycaemic control
may be lower than those required for improved
respiratory fitness. This does not necessarily exclude
the possibility of improved glycaemic control even
though respiratory fitness did not improve.
Most walks were not supervised and the patients
recorded only the time spent on each exercise session,
not the intensity. This lack of exactness concerning
exercise intensity is a weakness of our study. At the
same time it reflects the conditions and resources
available in primary health care, where most Swedish
type 2 diabetes patients receive counseling on lifestyle
matters.
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HDL and LDL cholesterol were equally improved
in the exercise group and in the control group. This
could not be explained by alterations in medication.
Some factor, other than exercise, probably accounts
for this improvement. Our study was conducted
between April–September and the improved HDL and
LDL cholesterol levels may have been a result of a
seasonal change. Other authors have reported
improved lipid levels during the summer months [20].
The SBP difference between the exercise and the
control groups on inclusion in the study raised the
question whether this difference was a reflection of
differing traditions of treatment for hypertension
between the two primary care practices where the
patients were listed. A survey of the records of 280 and
290 patients, respectively at the two primary care
practices, revealed no significant differences in blood
pressure levels between the two. Mean SBP (S.D.)
were 148.6 (19.9) and 146.3 (19.0), respectively
(unpublished data).
The nine patients in the intervention group who did
not increase their level of physical activity probably
illustrate the difficulties of obtaining adherence to
exercise programs pointed out by other authors [12–
14]. To three of those patients three walks per week
was less exercise than they did before the study started
and they had not altered their exercise habits after 4
months. They could therefore not be expected to
improve their risk factors in this study. Thus, 6 out of
26 patients did not reach the relatively modest exercise
goal of this study, which was conducted in a primary
care setting at short distances from the homes of the
patients. No special utensils were required for
exercising. We believe that exercise alternatives that
are easily available would provide the best opportu-
nities for the establishment of regular exercise habits.
A separate analysis of the 17 patients in the
intervention group who increased their amount of
exercise seems justified. It resembles a clinical
situation where some patients manage to adhere to
lifestyle recommendations and some do not. No
improvement of glucose control could be discerned in
this group, as was also the case for the entire inter-
vention group. However, systolic and diastolic blood
pressures and BMI were decreased to statistically
significant degrees.
The United States Centers for Disease Control and
Prevention recommend every US adult to accumulate
the equivalent of 30 min of brisk walking on most,
preferably all, days of the week [21]. Further studies
are needed to elucidate whether or not this recom-
mendation is consistent with improved glucose
metabolism in patients with type 2 diabetes.
The intensity and frequency of exercise, at which
effects on diabetes risk factors can be discerned, may
not be possible to define in terms of absolute threshold
values. It is also likely that the effect of increased
regular exercise depends on previous exercise habits.
The necessary amount of exercise can be expected to
differ between individuals and to appear on a sliding
scale between ‘‘no effect’’ and ‘‘maximum effect’’.
Mortality studies have demonstrated that great health
benefits can be achieved if unfit persons can improve
their degree of fitness by participating in moderately
vigorous exercise programs [22,23]. A sedentary
person that starts exercising can be expected to
improve his/her risk factors relatively more than a
well-trained person who makes a corresponding
increment in exercise intensity.
Motivation plays a central role in any medical
consultation concerning lifestyle alterations. This is
particularly true for the question of exercise in type 2
diabetes. The acute blood glucose reduction following
a 30 min walk, demonstrated in a previous study [24],
might provide motivational information to diabetes
patients, many of whom may not be accustomed to
exercising at all. When counseling a person with type
2 diabetes it may be tempting to suggest low intensity
exercise for psychological reasons. It might be
relevant to argue that ‘‘a little exercise is better than
none and more is better than a little’’. At the same time
it is important to provide the patient with such
substantial information that he or she can set realistic
goals for sustainable exercise habits.
Our results suggest that different levels of physical
activity may be required for the improvement of the
various risk factors in type 2 diabetes. Thus, in the
patients who increased their exercise levels a significant
decrease of SBP and DBP as well as BMI and total
plasma cholesterol levels occurred, without a corre-
sponding improvement of glycaemic control. More
detailed knowledge of the specific effects on diabetes
risk factors that can be obtained from regular physical
activities adds to the credibility of clinical advice
concerning the role of regular physical training as an
important part of the management of type 2 diabetes.
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Abstract
Aims To assess the effects of 4 months of increased physical activity on health-related quality of life in overweight individuals
with Type 2 diabetes mellitus, normal or impaired glucose tolerance.
Methods We included 212 individuals without severe physical or cardiovascular impairments aged 61 (57–64) years, with
BMI of 29 (27.5–32) kg ⁄m2. Numbers are median (25th–75th percentile). Subjects were stratified based on normal glucose
tolerance (n = 128), impaired glucose tolerance (n = 34)orType 2 diabetesmellitus (n = 50). Theywere randomized intoeither
a control group (n = 125), who maintained unaltered habitual lifestyle, or an exercise intervention group (n = 87), who were
directed toengage inNordicwalkingwithwalkingpoles, 5 hperweekover4 months. Self-reportedphysical activity andhealth-
related quality of life was assessed at the time of inclusion and after 4 months.
Results Baseline health-related quality of life of this study cohort was similar to, or better than, an age- and sex-matched
Swedish population sample, for 12 of 13 scales. Quality of sleep and BMI were improved for participants with normal glucose
tolerance after 4 months of Nordic walking, with little or no musculoskeletal pain as compared with control subjects. No
correlation was evident between improved quality of sleep and improved BMI.
Conclusions Quality of sleep improved in the group with normal glucose tolerance following 4 months of Nordic walking.
BMIreductiondidnot account for this improvement.Nordicwalking canbe introduced inaprimaryhealth care settingasa low-
cost mode of exercise that promotes weight loss and improved health satisfaction.
Diabet. Med. 28, 1362–1372 (2011)
Keywords exercise, heath-related quality of life, primary health care, sleep, walking
Abbreviations SDPP, Stockholm Diabetes Prevention Program; SWED-QUAL, Swedish health-related quality of life
questionnaire
Introduction
A sedentary lifestyle has become a major threat to public health
worldwide. Physical inactivity predisposes individuals to obesity
and Type 2 diabetes mellitus and often leads to premature death.
People diagnosed with Type 2 diabetes are typically middle-aged
or older, with a sedentary lifestyle. Daily exercise has been
considered a cornerstone in the lifestyle management of Type 2
diabetes and numerous studies have provided evidence for
reduced mortality and risk of cardiovascular disease in physically
active people, irrespective of the diabetic state [1–4]. Exercise
intervention promotes beneficial outcomes and positively
influences morbidity and mortality even in middle-aged
participants [5–7]. Moreover, regular walking, combined
with reduced caloric intake, has a diabetes-preventive effect in
individuals with impaired glucose tolerance [8–10].
Promoting a physically active daily life should have high
priority in primary healthcare counselling. A proactive
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intervention by primary care physicians could be a valuable
approach to reduce premature cardiovascular morbidity and
mortality and to delay, or even prevent, the development of
impaired glucose tolerance and Type 2 diabetes. However, an
older sedentary population with Type 2 diabetes is more
susceptible to painful conditions of the musculoskeletal system
[11]. Introducing physical activity as part of a daily regimen for
the treatment of Type 2 diabetes must therefore be initiated with
caution. Moreover, attention should be given to quality-of-life
aspects in assessing the benefits of an exercise programme on an
older, sedentary population with Type 2 diabetes.
The aim of this study was to determine if increasing daily
physical activity, in the form of Nordic walking with walking
poles, would influence health-relatedquality of life in overweight
individuals with normal glucose tolerance, impaired glucose
tolerance or Type 2 diabetes.
Subjects and methods
Patient recruitment
This investigation was a randomized, controlled study.
Recruitment was achieved through newspaper advertisements
andpersonal lettersof invitation to447 former participants in the
Stockholm Diabetes Prevention Program (SDPP) [12], living in
the catchment area of the primary healthcare centre of
Gustavsberg, a suburb outside Stockholm, Sweden. The study
spanned three consecutive summer seasons (2006–2008) and
occurred between May and September. New participants were
recruited each year. Two hundred and twelve individuals were
included (118 females and 94 males). Ninety participants
were recruited by advertisements and 122 were former SDPP
participants. The participants were stratified for state of glucose
tolerance (normal, impaired glucose tolerance and Type 2
diabetes) and subsequently randomized to either a control or
exercise-interventiongroup.Eachyear,newentries into the study
were randomized into control or intervention groups. For the
randomization procedure, blinded labels with the participants’
names were drawn from a box and assigned to either the control
or intervention group. Subjects randomized to the control group
were invited to participate in the intervention group the
following year. The subjects who joined the study in both
control (first entry) and intervention (second entry) groups are
represented only once in this work, as control subjects, skewing
the control ⁄ exercise groupnumbers.Thecontrol groupconsisted
of 125 ⁄212 individuals. The intervention group consisted of
87 ⁄212 individuals. Written informed consent was obtained
from all participants. The study was approved by the Ethics
Committee of Karolinska Institutet, Stockholm.
Biochemistry and anthropometry
At the time of inclusion and after 4 months, an oral glucose
tolerance test was performed. Plasma glucose was first
determined in the fasting state, prior to the ingestion of 75 g of
glucose in water solution, and again after 2 h, and calculated as
the mean of two capillary blood samples. We used a portable
HemoCue B-Glucose analyser (A¨ngelholm, Sweden) for this
purpose [13]. Glucose tolerance was classified as either normal
glucose tolerance < 8.9, impaired (impaired glucose tolerance)
8.9–12.1orType 2diabetes‡ 12.2 mmol ⁄ l, according to the2-h
level after one oral glucose tolerance test. Of the 212 subjects, 50
were classified as ‘Type 2 diabetes’, 34 as ‘impaired glucose
tolerance’ and 128 as ‘normal glucose tolerance’. The mean
duration (sd) of diabetes was 5 (4) years for subjects with Type 2
diabetes. Subjects who were previously diagnosed with diabetes
were classified as Type 2 diabetes regardless of the oral glucose
tolerance test outcome on inclusion in this study.
Body weight and height were assessed at the time of inclusion
and after 4 months. BMI was calculated by the formula body
weight (kg), divided by height (m) squared. A BMI of 18.5–
24.9 kg ⁄m2 was considered normal, 25–29.9 kg ⁄m2 overweight
and ‡ 30 kg ⁄m2 obese. Systolic and diastolic blood pressures
weredetermined in the seatedpositionby theuseofaSpeidell and
Keller tonometer (Jungingen, Germany). All measurements were
made in the morning, in conjunction with the oral glucose
tolerance test.
Inclusion criteria
Inclusion criteria were as follows: age 45–69 years, BMI
> 25 kg ⁄m2 and, for people with Type 2 diabetes, HbA1c
between 57 and 78 mmol ⁄mol [International Federation of
Clinical Chemistry (IFCC) standard], comparable with 7.4–
9.3% [National Glycohemoglobin Standardization Program
(NGSP) standard]. Exclusion criteria were physical impairment,
symptoms of angina pectoris (chest pain on physical strain),
atrial fibrillation determined by electrocardiogram systolic or
diastolic blood pressure > 160 or > 100 mmHg, respectively,
and insulin treatment.
Assessment of physical activity and intervention protocol
Exercise in this study was unsupervised. Self-reported exercise
was recorded at baseline and after 4 months. The participants
were asked to estimate their physical activity level during the
6 months prior to the study and during study participation using
a visual analogue scale to rank the frequency of physical activity
from 0 mm (none) to 100 mm (intensive daily activity).
The participants in the exercise group were instructed to
increase their weekly level of physical activity by 5 h of Nordic
walking for 4 months. Nordic walking is a unique fitness
technique that utilizes walking poles to involve the upper body in
the exercise, in addition to providing extra support. Participants
received verbal instructions for Nordic walking by a
physiologist ⁄personal trainer. The exercise group participants
were provided with a diary and asked to record date and number
of minutes for each bout of Nordic walking. To compare self-
reported physical activity with an objective assessment, 25
participants—11 control subjects and 14 intervention
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participants—agreed to wear a uniaxial accelerometer on the
hip, for 7 days during waking hours (ActiGraph model GT1M;
ActiGraph, Pensacola, FL, USA). This type of accelerometer
records physical activity as total activity counts per min and min
per day of inactivity, low, moderate or vigorous activity and is
considered a valid and reliable tool for measuring physical
activity in adults [14]. No instructions regarding eating habits or
nutrition were provided and no dietary intervention was
administered. The participants in the control group were
directed to continue their habitual daily activity.
Health-related quality of life assessment
A quality-of-life questionnaire was provided at the time of
inclusion and after 4 months. The Swedish health-related quality
of life questionnaire (SWED-QUAL) [15], adapted from the
Medical Outcomes Study [16], was used. Medical Outcomes
Study assessments are generic (as opposed to disease specific)
health-related quality of life questionnaires that present results as
a health profile. The 66 items of the SWED-QUAL provide the
basis for 13 scales that represent the following aspects of health-
related quality of life: physical functioning, satisfaction with
physical health, pain, role limitation attributable to physical
health, role limitation attributable to emotional health, positive
affect, negativeaffect, cognitive functioning, sleep, generalhealth
perception, family functioning, marital functioning and sexual
functioning. The multi-item scales are set between 0 and 100
points, where 0 indicates the lowest possible score and 100 the
highest. Inter-group differences of the SWED-QUAL results are
expressed in terms of statistical significance. Effect size is a
complementary method for identifying minimally important
differences of patient-reported outcomes. The minimally
important difference is defined as the smallest change in a
patient-reported outcome that is perceived by the patient as
beneficial. The effect size is defined by the formula: effect
size = (Mtreatment–Mcomparison) ⁄SDpooled, M = ‘mean’ i.e. ‘M
treatment’ = mean value after treatment ⁄ intervention. ‘M
comparison’ = mean value before treatment ⁄ intervention. An
effect size of 0.2 is considered small, 0.5 moderate and 0.8 is a
large change [17]. The SWED-QUAL has been used in previous
studies including patients with Type 2 diabetes [18,19].
A random sample of 2500 Swedish men and women, aged 18–
85 years, has previously answered the SWED-QUAL. Health
status and anthropometric data are not known for this Swedish
population sample. The SWED-QUAL results of each study
participant were matched, and compared with, the aggregated
results of all Swedish population sample individuals of the same
age and sex.
Statistical methods
The original power calculation, based on the assumed differences
in SWED-QUAL scales of 0 vs. 5 between the control and
intervention groups, with a = 0.05 and power = 0.8, indicated
that 63 participants would be required in each group. With the
skewed randomization, explained above, a power = 0.8 would
be obtained by 77 ⁄54 participants. In the group with normal
glucose tolerance, we included 75 ⁄53 individuals ( = power
0.7957). The study was underpowered for participants with
impaired glucose tolerance and those with Type 2 diabetes.
Stata statistical software (StataCorp., College Station, TX,
USA) was used to calculate differences. The score for each scale
was calculated as the median (25th–75th percentile) of the items
(questions) included in each of the 13 scales. Differences within
and between groups were calculated by non-parametric tests:
Wilcoxon’s signed-rank test for within-group comparisons and
Wilcoxon’s rank-sum test for between-group comparisons. Sex
differences between groups were calculated by v2-test. P-values
< 0.05 were considered statistically significant. Spearman’s rho
was determined for the assessment of correlation.
Results
Baseline data in Table 1 are presented separately for participants
with normal glucose tolerance, impaired glucose tolerance and
Type 2 diabetes. The 212 participants were 61 (57–64) years of
age, with a BMI of 29 (27.5–32) kg ⁄m2. Numbers are median
(25th–75th percentile). Fifty-three per cent of the study
participants were overweight (BMI 25.0–29.9 kg ⁄m2) and
47% were obese (BMI ‡ 30 kg ⁄m2). ANOVA reflected a
disease-state dependency for baseline levels of HbA1c
(P < 0.001), systolic blood pressure (P = 0.019) and BMI
(p = 0.0024). Diastolic blood pressure levels were, however,
similar between groups of varying glucose tolerance (P = 0.85).
The 50 participants with Type 2 diabetes reported baseline
health-related quality of life scores at the same level as the 128
participants with normal glucose tolerance, for all 13 SWED-
QUAL scales, when compared with Wilcoxon’s rank-sum test
(statistics not shown). Of the 50 participants classified as Type 2
diabetes, 45 were previously known to have Type 2 diabetes and
21 were taking anti-diabetic medication. Of the remaining five
individuals classified as Type 2 diabetes, two were again
classified as Type 2 diabetes according to the oral glucose
tolerance test at the end of the study. Two were classified as
having impaired glucose tolerance and one as having normal
glucose tolerance according to this second oral glucose tolerance
test. Ten participants withdrew from the study prior to the
conclusion. The principle of last-observation-carried-forward
was applied in those cases and their initial results were thus
included in the data analysis.
Followinga4-monthperiodof either sustained (control group)
or increased physical activity (Nordic walking, 5 h per week),
BMI was reduced by –1.0 (–1.0 to 0.0) kg ⁄m2 in the intervention
group with normal glucose tolerance and by 0.0 (–1.0 to 1.0)
kg ⁄m2 in the control group with normal glucose tolerance
(P = 0.0019). BMI did not change significantly in the groups
with impaired glucose tolerance or Type 2 diabetes (Table 2).
Visual analogue scale estimates of physical activity increased
significantly in the intervention groups with normal glucose
tolerance and Type 2 diabetes, by 30 (10–40) and 24 (10–40)
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mm, respectively, median,(25th–75th percentile), as shown in
Table 2. The calculated effect sizes were 1.0 and 0.8. Walking
diaries were obtained from 91% of the participants in the
intervention group and 78% of the participants with normal
glucose tolerance reported ‡ 80% (4 h ⁄week) of prescribed
Nordic walking. Corresponding figures for participants with
impaired glucose tolerance and Type 2 diabetes were 67 and
50%, respectively. Median values (25th–75th percentile) of
hours per week of Nordic walking were 4.7 (4.1–5.2), 4.6 (3.7–
6.0) and 3.8 (3.1–4.7) for the groups with normal glucose
tolerance, impaired glucose tolerance and Type 2 diabetes,
respectively. ANOVA did not indicate any significant difference
between the three groups (P = 0.1468). Comparison by
Wilcoxon’s rank-sum test showed a significant difference
between participants with normal glucose tolerance and those
with Type 2 diabetes (P = 0.0218), whereas comparisons
between participants with normal–impaired glucose tolerance
and impaired glucose tolerance–Type 2 diabetes showed no
significant differences in hours of Nordic walking per week
(P = 0.8702 and 0.1557, respectively).
Total counts per min, recorded by accelerometers, were 348
(220–528) for the control group (n = 11) and 466 (348–623) for
the intervention group (n = 14), P < 0.001, Wilcoxon rank-sum
test. Data are median (25th–75th percentile).
Quality of life was assessed with the SWED-QUAL
questionnaire before and after 4 months of control or exercise
intervention. Results of the intention-to-treat analysis of the
SWED-QUAL are presented in Table 2, parallel with
corresponding data from an age- and sex-matched Swedish
population sample. At baseline, the group with normal glucose
tolerance including both control and intervention participants
scored significantly higher for eight SWED-QUAL scales
[physical functioning (effect size = 0.4), satisfaction with
physical functioning (0.4), role limitation because of physical
health (0.2), positive affect (0.2), cognitive functioning (0.2),
sleep (0.2), general health ([0.3) and sexual functioning (0.4)],
compared with the Swedish population sample. For the
remaining five scales, the baseline scores did not differ between
the group with normal glucose tolerance and the Swedish
population sample. The group with impaired glucose tolerance,
including both control and intervention participants, scored
significantly higher than the Swedish population sample for
physical functioning (0.4), cognitive functioning (0.3), family life
(0.6) and sexual functioning (0.5). For the other nine scales, there
were no significant differences between participants with
impaired glucose tolerance and the Swedish population sample.
The group with Type 2 diabetes scored significantly higher for
sexual functioning (0.3) than their Swedish population sample
counterparts.
Quality of sleep and general health improved significantly in
the normal glucose tolerance intervention group, compared
with the normal glucose tolerance control group; effect size 0.4
and 0.1, respectively. In the Type 2 diabetes intervention
group, satisfaction with physical functioning and sleep
improved significantly; effect size 0.7 and 0.5, respectively.Ta
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Correlation analysis showed no significant relationship
between change of quality of sleep and change of BMI
(Spearman’s rho –0.12).
Discussion
The findings of this study provide evidence that overweight
Swedish individuals with normal glucose tolerance, impaired
glucose tolerance or Type 2 diabetes report health-related
quality of life at the same level as, or better than, an age- and
sex-matched Swedish population sample. The participants in this
study did not suffer from any severe physical or cardiovascular
impairment that limited daily activity. Moreover, their blood
pressure was within, or near normal range and glucose metabolic
control was within the acceptable range for the participants with
Type 2 diabetes (Table 1). Other studies have reported impaired
health-related quality of life in people with Type 2 diabetes [20].
The most prominent factors that negatively affected health-
related quality of life in people with Type 2 diabetes were
macrovascular disease (coronary heart disease and stroke),
psychiatric disorders (depression) and musculoskeletal disorders.
In the absence of co-morbidity or diabetes complications, Type 2
diabetesdoes notdirectly impair health-relatedqualityof life. It is
noteworthy that the participants with normal glucose tolerance
in our study scored significantly higher than the Swedish
population sample cohort for eight SWED-QUAL scales,
whereas the participants with impaired glucose tolerance
scored significantly higher than the Swedish population sample
cohort for four scales and the participants with Type 2 diabetes
forone scale.Thismight imply thathealth-relatedqualityof life is
impaired by a worsened state of glucose tolerance. However, the
number of participants with impaired glucose tolerance and with
Type 2 diabetes in this study was rather low compared with the
group with normal glucose tolerance. This result should
therefore be interpreted with caution.
Although quality of sleep at baseline was at the same level, or
better, inour studygroupcompared with theSwedish population
sample, this variable improved significantly after 4 months of
increased physical activity, whereas it tended to worsen in the
control group. The control group with Type 2 diabetes reported
a pronounced worsening of quality of sleep. We have no
satisfactory explanation for this. There were no indications of a
worsened state of diabetes during the time of study that might
otherwise have offered an explanation. BMI was significantly
lowered in the intervention group, but there was no correlation
between improved quality of sleep and lowered BMI. An increase
of physical activity may therefore have a positive effect on the
quality of sleep.
A report on the treatment of insomnia in adult Swedish citizens
has recently been published by the Swedish Council on Health
Technology Assessment [21]. Insomnia, defined as difficulty in
falling asleep or early awakening more than three times per week,
was reported by 24% of study participants. Moreover, 11%
reported impaired daytime quality of life as a result of disturbed
night-time sleep. Furthermore, a questionnaire focusing on
insomnia was randomly distributed to Swedish primary care
physicians. The responding physicians (n = 352) reported seeing
two or more patients per week who requested care for insomnia,
more than half of whom were over 65 years of age. Medication
for sleeping disorders was prescribed for approximately 8% of
adult Swedish citizens in 2008 and to elderly people, often for
long-term use. There is concern that the persistent use of certain
hypnotic drugs may lead to problems of adverse effects and
addiction over time. Thus, Nordic walking and other modes of
exercise may provide a less costly and safer alternative to
medication as a means of alleviating some sleep disorders. The
Swedish Council on Health Technology Assessment report
concludes that the evidence for physical activity and other
alternative methods for treating insomnia are insufficient and
therefore further research is warranted.
Qualityofsleepappearstobeasensitivemarkerofholisticwell-
being, possibly reflecting the influence of somatic disease and
various factors of psychosocial stress. Individuals with Type 2
diabetes whose medical health deteriorated over 4 years have
showndeterioratingqualityofsleep[22].Astudyofpsychological
distress identified insomnia as one psychological stress factor
contributing to the increased risk of developing pre-diabetes and
Type 2 diabetes in Swedish middle-aged men, but not in women
[12]. A reduced risk of sleep disorders in men and women who
participated in physical activity at least once a week, and in men
whowalkedatabriskpaceformorethansixblocksdailyhasbeen
reported [23]. Studies measuring sleep physiology in individuals
with or without daily exercise have been contradictory, as
assessed in a meta-analytic review. Total sleep time and
slow-wave sleep seemed to increase as a result of exercise,
whereas rapid eye movement sleep and sleep onset latency was
decreased[24].Theassociationsbetweenshortsleepdurationand
increased prevalence of Type 2 diabetes and hypertension have
been described [25,26]. It has been suggested that the common
mechanism may be an over-secretion of adrenocorticotrophic
hormone and cortisol, and that activation of the hypothalamic–
pituitary-adrenal axis in these patients may play a role [24,25].
Hypothalamic–pituitary-adrenal axis activation is regarded as
an effect of various stress factors, and hypothalamic–
pituitary-adrenal hyperactivity has been suggested to promote
the development of insulin resistance, central obesity,
dyslipidaemia, hypertension and Type 2 diabetes [27].
An association of excess weight and impaired health-related
quality of life has been described [28,29]. The authors provide
evidence that physical aspects of health-related quality of life are
negatively affected by excess weight or obesity. The results of our
study do not indicate that overweight per se, in the absence of
other disabling conditions, impairs health-related quality of life.
The participants with Type 2 diabetes did not report increased
pain in comparison with Swedish population sample
counterparts (Table 2). This finding is highly relevant, as
painful conditions of the musculoskeletal system are more
prevalent in people with Type 2 diabetes than in those without
Type 2diabetes [11].Musculoskeletal painwas aprimary reason
for subject withdrawal from a Dutch study of a medical fitness
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programme for patients with Type 2 diabetes [30]. Reported
pain did not increase in exercise participants with normal glucose
tolerance, impaired glucose tolerance or Type 2 diabetes in our
study. No participant left the study for reasons involving
musculoskeletal pain. Nordic walking may thus be a safe mode
of introductory exercise, even for individuals with Type 2
diabetes.
Limitations of this study
Four months’ intervention is potentially too brief for measurable
effects to occur on some of the aspects ofhealth-related quality of
life under study. Long-term studies of similar exercise intensity
and frequency are warranted to elucidate whether Nordic
walking may be a sustainable mode of exercise, and whether it
produces a more pronounced effect on health-related quality of
life than in this brief intervention study.
The daily physical activity of participants in this study, prior to
entry and during the study, was not uniform or controlled or
matched. Self-reported level of physical activity at baseline varied
considerably. This factor may have diminished the perceived
exercise effects on health-related quality of life. The addition of
Nordic walking may not have a substantial effect on quality of
life to a person who was moderately physically active before
inclusion in this study. In future studiesof this kind,basal exercise
exclusion criteria will be considered.
Exercise was not controlled and self-reporting of daily
exercise, as carried out in this study, is not as accurate as
supervised activities. Moreover, the visual analogue scale,
utilized for estimating the frequency of daily physical activity,
has not been validated as a measure of physical activity. In
addition, some physical exercise normally undertaken may have
been replaced by Nordic walking, thus diminishing the intended
increase of physical activity during the time of study.
The numbers of participants with impaired glucose tolerance
and Type 2 diabetes were too low to allow conclusions of
statistical significance for these groups. The results of this study,
indicating lower SWED-QUAL scores for people with impaired
glucose tolerance and Type 2 diabetes, compared with
participants with normal glucose tolerance must therefore be
interpreted with caution.
The fact that more than half of the participants had previously
been involved in the SDPP could theoretically have created some
bias in our findings. The SDPP was not, however, an
interventional study on the individual level and comprised no
elements of lifestyle intervention. Moreover, the SWED-QUAL
questionnaire was not used in the SDPP survey. Awareness of
being overweight was an expressed concern and reason for the
majority of individuals to participate in this study. It would seem
unlikely that the former participation in the SDPP could
somehow influence the results of this study.
Baseline classification of normal glucose tolerance, impaired
glucose tolerance or Type 2 diabetes was based on one oral
glucose tolerance test only. The diagnosis of asymptomatic
diabetes in clinical practice would require the confirmation by a
second oral glucose tolerance test. For the 45 participants with a
diagnosis of Type 2 diabetes established prior to the time of
inclusion in this study, a second oral glucose tolerance test would
be redundant. Five participants were classified as ‘previously
unknown Type 2 diabetes’ and, for two individuals in this
group, the diagnosis was confirmed by a second oral glucose
tolerance test at the end of the study. The remaining three
individuals were classified as ‘impaired glucose tolerance’ (2) and
‘normal glucose tolerance’ (1) after the second oral glucose
tolerance test.
Strengths of this study
This study was undertaken in a primary care setting. It can serve
as an example of how exercise could be introduced to selected
patients who might profit from a more physically active lifestyle.
The participants were responsible for their own exercise
schedules and the study did not involve costly supervision of
exercise sessions. The exercise participants received instructions
from a personal trainer for Nordic walking at baseline and one
supportive telephone call after 2 months from an assistant nurse.
Although not a very strenuous mode of exercise, Nordic
walking is more strenuous than brisk walking as the use of
walking poles also activates the muscles of the upper limbs. It
may therefore suit people who are unaccustomed to exercising.
Our experience was that Nordic walking did not cause adverse
reactions of musculoskeletal pain.
Three different means of reporting physical activity were
used in this study: visual analogue scales, exercise diaries and
accelerometers. All methods indicated that the intervention
group was more physically active than the control group.
Although the intensity of exercise was not well established, we
can reasonably assume that the self-reported amount of exercise
has been a rather accurate account of actual exercise
performed, based on the subjects who also used accelerometer
reporting.
Future research
The implementation of sustainable, regular exercise habits is a
challenging undertaking. Exercise on prescription is presently
practised in Swedish primary health care, and has been shown to
promote increased self-reported physical exercise and improved
quality of life [31]. Our results imply that a small increment of
regular physical activity does not impair health-related quality of
life. In our study, health-related quality of life tended to improve
following exercise intervention. This experience could be used in
clinical efforts of motivating patients to assume a more physically
active life, a factor of utmost importance in health counselling of
people with excess weight, disturbed glucose metabolism,
hypertension and other cardiovascular risk factors. Introducing
regular exercise to individuals unaccustomed to exercise training
or suffering from cardiovascular disease should be done with
care, taking into account the risks of cardiovascular or
musculoskeletal complications.
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Future studies of health-related quality of life in relation to
physical activity should involve supervised exercise and
participants with a somewhat uniform, and low, level of
habitual exercise habits at inclusion. Elucidating whether
people with impaired glucose tolerance or Type 2 diabetes are
less responsive to the effects of regular exercise is clinically
relevant and sufficient numbers of participants with normal
glucose tolerance and Type 2 diabetes should be included.
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Abstract 
The effects of Nordic walking on cardiovascular risk factors were determined in 
overweight individuals with normal or disturbed glucose regulation. We included 213 
individuals, aged 60±5.3 years, with BMI 30.2±3.8 kg/m2 and normal glucose 
tolerance (NGT, n=128), impaired glucose tolerance (IGT, n=35) or type 2 diabetes 
mellitus (T2DM, n=50). Participants were randomized to unaltered physical activity 
or to five hours per week of Nordic walking with poles, for a four-month period. 
Dietary habits were unaltered. BMI, waist circumference, blood pressure, glucose 
tolerance, clinical chemistry, maximal oxygen uptake (peak VO2) and self-reported 
physical activity (questionnaire) were assessed at the time of inclusion and after four 
months. The intervention participants kept a walking diary. In the NGT exercise 
group, self-reported physical activity increased markedly and body weight (–2.0±3.8 
kg), BMI (–0.8±1.4 kg/m2) and waist circumference (–4.9±4.4 cm), (mean±SD) 
decreased. Exercise power output (12.9±9.9 W) and peak VO2 (2.7±2.8 ml × kg–1 × 
min–1) increased in the IGT exercise group. More cardiovascular risk factors were 
improved in people with NGT compared with IGT or T2DM. Exercise capacity 
improved significantly in all three groups among participants at least 80% compliant 
with scheduled exercise time. Nordic walking improved anthropometric 
measurements and exercise capacity. However, unsupervised Nordic walking may not 
provide sufficient exercise intensity to achieve ultimate health-promoting benefits on 
the cardiovascular parameters assessed in this study, particularly for those with 
disturbed glucose regulation. 
 
Keywords: Cardiovascular Risk Factors, Exercise, Primary Health Care, Walking 
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INTRODUCTION 
Lifestyle changes involving exercise and food intake constitute conventional 
treatment of type 2 diabetes mellitus (T2DM). Regular walking, combined with 
reduced caloric intake, can prevent T2DM in people with impaired glucose tolerance 
(IGT) [1-3]. Prospective cohort studies of people with [4-6] and without [7] T2DM 
have provided evidence for reduced mortality in physically active, compared with 
more sedentary individuals. Regular physical exercise has beneficial effects on 
cardiovascular risk factors in people with T2DM [8]. However, adherence remains an 
issue, since patients with T2DM often fail to comply with exercise programs, due to 
musculoskeletal complications and poor motivation [9].  
A meta-analysis of 27 studies, comprising 1,003 individuals with T2DM, provided 
evidence for a 0.8±0.3% reduction in HbA1c following aerobic and/or resistance 
training lasting for ≥12 weeks [10]. Many lifestyle intervention studies involve 
relatively intense exercise programs and expensive supervision, employing highly 
trained personnel. Thus, studies aimed at establishing low-level exercise programs to 
prevent cardiovascular risk are warranted.  
In a previous study of people with T2DM, we provided evidence that four months 
of walking intervention, 45–60 minutes three times per week, was insufficient to 
improve cardiovascular risk factors [11]. We speculated that an exercise prescription 
of greater frequency and intensity than three hours per week of walking would be 
necessary to induce health benefits in overweight T2DM patients. Nordic walking 
with poles activates the muscles of the upper limbs and increases oxygen 
consumption, caloric expenditure and heart rate [12]. Applying this type of exercise, 
we studied a cohort of individuals with varying degrees of glucose regulation, 
including people with normal glucose tolerance (NGT), IGT and T2DM. The study 
participants increased not only the exercise intensity, but also the number of 
individual exercise sessions compared to our previous study.  
PATIENTS AND METHODS  
Patients 
Inclusion criteria were age 45 to 69 years, BMI >25 kg/m2, and HbA1c for 
individuals with T2DM between 7.4 and 9.3% NGSP standard (57 to 78 mmol/mol 
International Federation of Clinical Chemistry (IFCC) standard). Exclusion criteria 
were physical impairments, symptoms of angina pectoris, i.e. chest pain on physical 
strain, atrial fibrillation determined by ECG, systolic or diastolic blood pressure >160 
or >100 mmHg respectively and insulin treatment. Insulin treatment was an exclusion 
criterion since it would interfere with the calculation of insulin resistance. 
Recruitment was achieved by newspaper advertising and letters of invitation to 447 
former participants in the Stockholm Diabetes Prevention Program (SDPP) [13] 
living in the catchment area of the primary health care center of Gustavsberg, a 
suburb outside Stockholm, Sweden. Examinations of the participants were performed 
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at the primary health care center and at the Department of Clinical Physiology, 
Karolinska University Hospital, Stockholm.  
A total of 213 individuals were included, 123 former SDPP participants and 90 
newly recruited participants from advertisements. Upon inclusion in the study, the 
participants were classified on the basis of one oral glucose tolerance test (OGTT) 
into either T2DM (n=50), IGT (n=35), or NGT (n=128). Forty-five individuals were 
previously classified as T2DM. The duration of diabetes was 5.1±3.7 years for people 
with T2DM (mean ±SD). The participants were stratified for state of glucose 
tolerance (NGT, IGT, or T2DM) and randomized to a control or exercise-intervention 
group. For the randomization procedure, blinded labels with the participants’ names 
were drawn from a box and assigned to either the control or intervention group. The 
time of study spanned three consecutive summer seasons (2006–2008), between May 
and September. Each year new entries into the study were randomized into control 
(unaltered physical activity) or intervention (Nordic walking) group. Individuals 
randomized to the control group were invited to participate in the intervention group 
the following year. Those who joined the study in both control (first entry) and 
intervention (second entry) groups are represented only once in this work, as control 
subjects, thus skewing the control/exercise group numbers. The control group 
consisted of 126/213 individuals. The intervention group consisted of 87/213 
individuals.   
Study Protocol 
This was a randomized controlled study. The participants in each category (NGT, 
IGT or T2DM) were randomized to the exercise or control group and asked to 
maintain their usual eating habits. The participants in the exercise group were 
instructed to increase their weekly level of physical activity by 5 hours of walking 
with poles (Nordic walking) for 4 months. An exercise physiologist provided 
instructions for Nordic walking. Walking intensity was prescribed as a pace that 
caused slight shortness of breath and perspiration. After two months the participants 
in the intervention group received a supportive telephone call from an assisting nurse. 
Written informed consent was obtained from all participants. The study was approved 
by the Ethics Committee of Karolinska Institutet, Stockholm.  
Basic characteristics 
Body weight was measured with an electronic scale (Hugin, Mustelia, EB5011). 
Systolic (SBP) and diastolic (DBP) blood pressures were determined, to the nearest 5 
mm Hg, in the seated position (Speidell & Keller Tonometer).  
Clinical Chemistry 
At the time of inclusion, one OGTT was performed. Plasma glucose was determined 
in the fasting state as the mean of two capillary blood samples prior to the ingestion 
of 75 g of glucose in water solution and again after 2 hours. Glucose was assessed 
with a HemoCue B-Glucose analyzer [14]. The 2-hour OGTT level was used to 
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classify the participants as NGT (<8.9 mmol/l), IGT (8.9 to 12.1 mmol/l), or T2DM 
(≥12.2 mmol/l). Participants previously diagnosed with diabetes were classified as 
T2DM regardless of the OGTT outcome on inclusion in this study. Venous blood 
samples were obtained in the fasting state and analyzed for total cholesterol, HDL 
cholesterol, LDL cholesterol, triglycerides, and HbA1c at the Laboratory of Clinical 
Chemistry at Karolinska University Hospital, Stockholm. Fasting serum insulin was 
determined using an adipokine (HADK2-61K-B09) assay kit from Linco Research 
(Electra-Box Diagnostica AB, Tyresö, Sweden), according to the manufacturer’s 
protocol. Plasma samples from each subject were extracted from whole blood and 
analyzed in duplicate. Results were quantified using the Luminex Bio-Plex 200 
system (Bio-Rad, Stockholm, Sweden). Insulin resistance was calculated, using the 
HOMA IR model [15], as fasting insulin (µU/ml) × fasting glucose (mM)/22.5.  
Exercise test  
Bicycle exercise tests were performed using a Rodby ergometer RE 820/830. Before 
the exercise test, the subjects sat on the bicycle for one minute and thereafter pedaled 
without load for another minute to obtain a steady baseline. The initial work load was 
set at 50 W and was increased by 10 W/min. A SensorMedics ergospirometer Vmax 
Encore (SensorMedics Corporation; Yorba Linda, USA) was used to measure gas 
exchange. The gas analyzers were calibrated with two calibrated gases containing 
16% O2, 4% CO2 and 26% O2, 0% CO2. Oxygen uptake (VO2) was calculated breath 
by breath, and the mean value for the latest 30 seconds was used. The VO2 at peak 
exercise (peak VO2) was determined at the point of subjective exhaustion.  
Self-reported physical activity 
Self-reported exercise was registered for control and intervention participants at 
baseline and after four months. The participants were asked to indicate, in a 
questionnaire, an estimate of low, medium and high intensity physical activity. The 
question was: How often do you perform physical activities, more than 30 minutes at 
a time? Low, medium and high intensity physical activities were specified as low = 
not strenuous (e.g. bowling, golf, slow walk, slow bicycle ride, light gardening), 
medium = strenuous but still allowing you to continue a conversation (e.g. tennis, 
dancing, horseback riding, brisk walk, strenuous gardening) and high = strenuous 
enough to cause sweating, increased heart rate and pronounced shortness of breath 
(e.g. aerobics, workout, jogging, fast bicycle ride). Alternative answers were: never, 
irregularly, once a week, twice a week, > 2 times a week. The participants in the 
exercise group were also asked to record in the exercise diary the duration and date of 
each Nordic walking bout. The extent to which the intervention participants fulfilled 
the prescribed amount of Nordic walking was determined from analysis of the 
exercise diaries.  
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Accelerometer 
To compare self-reported physical activity with an objective assessment, 25 
consecutive participants (n=11 from the control group and n=14 from the intervention 
group) agreed to wear an accelerometer (ActiGraph model GT1M; ActiGraph, 
Pensacola, Florida, USA), in a belt around the waist, for seven days from morning to 
bedtime, shortly after randomization [16]. Physical activity was recorded as total 
activity counts per minute, minutes per day of inactivity, low, moderate, or vigorous 
activity.  
Statistics  
A paired t-test was used to analyze within-group differences and two-sample t-test for 
between-group differences. Differences of sex distribution, medication and physical 
activity levels were analyzed by χ2 or Fisher’s exact test. A p value of ≤0.05 was 
regarded as statistically significant. For statistical analyses Stata statistical software 
(Stata Corporation, College Station, Texas, USA) was used. Follow-up data were 
missing for 10 participants and the principle of last-observation-carried-forward was 
applied in those cases. Analysis was performed as intention-to-treat. 
Power calculation 
The power calculation was based on the number of study participants required to 
meet the statistical needs of a Quality of Life questionnaire, not reported in this 
article. The assumed differences in HbA1c of 0 versus –0.5%, between control and 
intervention T2DM participants, with α=0.05 and power 0.8, indicated that 17 
individuals with T2DM would be required in each group.  
RESULTS 
Baseline characteristics and medication 
Baseline parameters are presented in Table 1. Self-reported high-intensity physical 
activity was significantly more frequent in the NGT control group than in the NGT 
intervention group. The total cholesterol level was lower and lipid-lowering statin 
medication was more frequent in the NGT intervention group, compared with the 
NGT control group. The triglyceride levels were lower in the T2DM control group 
but statin medication did not differ from that in the T2DM intervention group. There 
were no other significant differences between the control and intervention groups.  
Medication was altered for four participants, all allocated to intervention; one NGT, 
two IGT, and one T2DM participants. Two were started on anti-hypertensive 
treatment and two altered their anti-hypertensive treatment. Blood pressure levels at 
the end of the study were not included for those four participants. Baseline SBP and 
DBP readings were carried forward according to intention-to-treat practice.  
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Effects of Nordic walking 
Body weight, BMI, waist circumference, and self-reported physical activity were 
improved (p=0.0042, 0.0051, 0.0006, and <0.001 respectively), in the NGT exercise 
group compared with the NGT control group (Table 2). Exercise capacity was 
improved in the IGT exercise group; power output (p=0.0011) and peak VO2 
(p=0.0338), compared with the IGT controls. Self-reported high-intensity physical 
activity was improved (p=0.012) in the T2DM exercise group, compared with the 
T2DM control group. Blood pressure, blood lipids, HbA1c, and HOMA insulin 
resistance were unaltered between the NGT, IGT, and T2DM exercise and control 
groups. In the T2DM exercise group, however, the HbA1c, the 2h post OGTT plasma 
glucose levels and exercise power output improved in the intra-group analysis 
(p=0.0359/0.0391, 0.0062 and 0.0118 respectively). The results presented in Tables 1 
and 2 were not altered by a multivariate linear regression analysis, adjusting for age, 
sex, and glucose tolerance (NGT, IGT, and T2DM), data not shown. 
Reported exercise time and effects of high adherence 
Hours per week of Nordic walking, according to exercise diaries, were: 4.7±1.5, 
4.8±1.8, and 3.9±1.4 for the NGT, IGT and T2DM exercise groups respectively 
(p=0.1468 by ANOVA). Among the 25 persons wearing accelerometers, the exercise 
group (n=14) was more physically active than the control group (n=11). Total activity 
counts per minute were 496±210 for the exercise group versus 382±196 for the 
control group (p=0.0004 by two-sample t-test). Corresponding data for total activity 
counts per day were 439376±197888 and 349580±193073 (p=0.0035), inactive 
minutes per day 494±104 and 529±109 (p=0.0322), and vigorous activity minutes per 
day 7.9±17.8 and 1.4±6.3 (p=0.0028). Data from diaries and accelerometers are not 
included in Table 2.  
Adherence to the exercise program varied within the intervention group. Therefore 
we performed a separate analysis for the 55 participants in the exercise group who 
reported ≥80% of the prescribed time of Nordic walking in their exercise diaries. In 
this group, exercise capacity (power output and/or peak VO2) significantly improved 
for the NGT, IGT and T2DM participants, compared with their respective control 
groups (Table 2). Improvement of body weight, BMI and waist circumference was 
similar to that of the entire NGT, IGT and T2DM exercise groups. 
Withdrawal Rate 
Ten individuals left the study before follow-up examination; 7 female (5 NGT, 1 IGT, 
1 T2DM, 5 intervention and 2 control) and 3 male (1 IGT, 2 T2DM, 1 intervention, 2 
control). Their baseline data were included in the intention-to-treat analysis. The 
motives for leaving were personal reasons/lack of time (4), medical reasons (4), and 
unknown (2).  
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DISCUSSION 
Our primary finding is that a four-month unsupervised Nordic walking program 
improved body weight, BMI, and waist circumference in people with NGT (Table 2). 
Moreover, exercise capacity was improved in participants who reported ≥80% of the 
prescribed exercise.  
Obesity was one risk factor common to all participants. The exercise intervention 
reduced weight, BMI and waist circumference in people with NGT, but not in those 
with IGT or T2DM. However, the IGT and T2DM groups were rather small 
compared with the NGT group. Visceral fat is a predictor of mortality [17] and waist 
circumference may be one simple measure of cardiovascular risk factors to gauge 
improvement following a period of physical activity. Our findings suggest that 
exercise intervention has a more pronounced effect on the anthropometric risk factors 
in people who do not have derangements in glucose metabolism.  
Individuals in the IGT and T2DM ≥80% exercise groups (Table 2) did not report 
increased frequency of medium, nor high, intensity physical activity, while the NGT 
participants did. Exercise power output, however, improved in people with IGT or 
T2DM, but not in people with NGT, in the intention-to treat-analysis. The 
discrepancy between reported physical activity and exercise power output may be due 
to other physical activities being replaced by Nordic walking, or recall bias. 
Furthermore, the increased power output among the NGT control participants was 
substantial, which can explain the non-significant difference between NGT control 
and intervention groups with respect to exercise capacity. A habitual increase in 
physical activity during the summer months among the NGT control group 
participants may account for this difference. Data from the physical activity 
questionnaires, Nordic walking diaries, accelerometers, and exercise capacity tests 
indicate a pronounced increase in physical activity in all three intervention groups.  
Due to the increasing number of individuals with, or at risk of developing T2DM 
[18], cost-effective healthy lifestyle programs are warranted. Improving or 
maintaining a high level of physical activity or physical fitness, reduces all-cause and 
cardiovascular death [7, 19]. The identification of key cardiovascular risk factors that 
are improved following a physical activity program is therefore of relevance. 
Exercise-referral and exercise on prescription have been practiced in the USA, the 
United Kingdom, and Scandinavia over the past 10–20 years, often in primary health 
care, and this may have led to increased physical activity levels [20-22].  
The exercise intensity prescribed in this study may have been too mild, or of 
insufficient structure to achieve robust improvements in blood pressure, lipid levels 
or glucose metabolic control. Notably in the intra-group analysis of the T2DM 
exercise participants, the 2-hour OGTT p-glucose, HbA1c and exercise power output 
improved, compared with the control group, although the difference did not reach 
statistical significance (Table 2). The exercise protocols reported in a recent meta-
analysis of 27 studies [10] included supervised exercise sessions, providing aerobic or 
resistance training programs that were more structured and strenuous than the Nordic 
walking program described in this study. Moreover the meta-analysis only included 
T2DM patients [10], whereas our study included individuals with NGT and IGT, 
which may explain the lack of improvement in overall glucose metabolic control 
(HbA1c) in this study. Nordic walking, five hours per week, may constitute a 
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minimum of exercise required for positive effects on cardiovascular risk factors 
studied here.  
The reduced waist circumference noted in the NGT, IGT and T2DM control groups 
(Table 2) may reflect the fact that this study was performed during the summer 
months when people tend to be more physically active. The improved fasting glucose 
and 2-hour post-OGTT glucose values in the T2DM control group may possibly be 
explained by improved dietary habits (e.g. more vegetables and fruit), since neither 
exercise capacity nor self-reported physical activity were improved in that group.  
Strengths and limitations of this study 
We employed a low-cost model of exercise feasible for primary health care. While 
exercise protocols of greater intensity such as aerobics and/or resistance training [10, 
23, 24], or home-based bicycle training [25], can yield a stronger beneficial outcome, 
the relatively low level of physical activity prescribed in this study could be achieved 
without occurrence of musculoskeletal complications in the NGT, IGT or T2DM 
participants, and without reported pain, which is more prevalent with T2DM [26]. 
Thus, Nordic walking may offer a safe mode of introductory exercise, even for people 
with T2DM.  
Reported levels of physical activity at baseline varied considerably. Thus, the pre-
existing (high) exercise levels of some participants may have limited the adaptive 
response to the Nordic walking. This study involved unsupervised, self-reported 
exercise. Whether the participants in the intervention group added Nordic walking to 
their pre-study daily activities, or replaced former exercise habits by Nordic walking, 
is unknown.  
A greater number of participants would have strengthened the statistical power of 
this study, particularly in the IGT and T2DM groups. The participants in this study 
were mainly recruited from the catchment area of one primary care center during 
three consecutive years. IGT participants are particularly difficult to identify, since 
impaired glucose tolerance is not a common diagnosis in primary health care. 
Food intake was not addressed in this study, but changes in dietary habits may have 
influenced the outcome. Indeed the increase in physical activity may alter food intake 
to some degree. However, the focus of this investigation was on the effects of 
exercise per se, and consequently we did not estimate the daily calorie intake of the 
study participants. 
Future implications 
Nordic walking is feasible for individuals unaccustomed to regular exercise. The 
improvement of body composition and physical fitness achieved following a 
relatively short period of moderately intense exercise could act as an incentive for 
overweight people to adopt a more physically active lifestyle. With supervised 
exercise, accompanied by motivational counseling focused on behavior changes, 
adherence to the program and clinical parameters may be enhanced. With an initial 
“trial” or “run-in” period it may be possible to identify, and exclude, individuals who 
are unable to adhere to an exercise program. The results of such a study would 
thereby be a more accurate reflection of the effects of the mode of exercise under 
78 
analysis. An improved study model for probing the effects of low/moderate physical 
activity should strive to include participants with more pronounced cardiovascular 
and metabolic risk factors to achieve a true representative picture of a primary care 
patient cohort. Our results may be used to support public health efforts to promote 
regular exercise. Physical activity on prescription issued at primary health care units 
may provide a tool for such support. Further studies are necessary to arrive at more 
precise exercise prescriptions that fully benefit individuals with obesity and/or 
metabolic disturbances.  
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The delicate homeostatic balance between glucose and fatty acid metabolism in relation to
whole-body energy regulation is influenced by mitochondrial function. We determined
expression and regulation of mitochondrial enzymes including pyruvate dehydrogenase
kinase (PDK) 4, PDK2, carnitine palmitoyltransferase 1b, and malonyl–coenzyme A
decarboxylase in skeletal muscle from people with normal glucose tolerance (NGT) or
type 2 diabetesmellitus (T2DM). Vastus lateralis biopsies were obtained fromNGT (n = 79) or
T2DM (n = 33) men and women matched for age and body mass index. A subset of
participants participated in a 4-month lifestyle intervention program consisting of an
unsupervised walking exercise. Muscle biopsies were analyzed for expression and DNA
methylation status. Primary myotubes were derived from biopsies obtained from NGT
individuals for metabolic studies. Cultured skeletal muscle was exposed to agents
mimicking exercise activation for messenger RNA (mRNA) expression analysis. The
mRNA expression of PDK4, PDK2, and malonyl–coenzyme A decarboxylase was increased
in skeletal muscle from T2DM patients. Methylation of the PDK4 promoter was reduced in
T2DM and inversely correlated with PDK4 expression. Moreover, PDK4 expression was
positively correlated with body mass index, blood glucose, insulin, C peptide, and
hemoglobin A1c. A lifestyle intervention program resulted in increased PDK4 mRNA
expression in NGT individuals, but not in those with T2DM. Exposure to caffeine or
palmitate increased PDK4 mRNA in a cultured skeletal muscle system. Our findings reveal
that skeletal muscle expression of PDK4 and related genes regulating mitochondrial
function reflects alterations in substrate utilization and clinical features associated with
T2DM. Furthermore, hypomethylation of the PDK4 promoter in T2DM coincided with an
impaired response of PDK4 mRNA after exercise.
© 2012 Elsevier Inc. All rights reserved.
M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 1 ( 2 0 1 2 ) 1 7 5 – 1 8 5
Author contributions: All authors contributed extensively to this paper. SSK performed experiments, analyzed data, and contributed to
discussion. FS performed experiments and analyzed data. TF recruited patients and performed clinical analysis. JRZ designed the study
and contributed to discussion and writing of the manuscript. AK contributed to discussion and data analysis and wrote the manuscript.
MEO performed experiments, analyzed data, and contributed to discussion and writing of the manuscript.
⁎ Corresponding author. Tel.: +46 8 524 87824; fax: +46 8 33 54 36.
E-mail address: Anna.Krook@ki.se (A. Krook).
0026-0495/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.metabol.2011.06.014
Ava i l ab l e a t www.sc i enced i r ec t . com
Metabolism
www.metabo l i sm jou rna l . com
1. Introduction
Skeletal muscle substrate metabolism plays a fundamental
role in whole-body nutrient utilization and homeostasis.
Metabolic flexibility, defined by the ability to switch between
lipid and glucose oxidation in response to a meal or after
insulin stimulation, is impaired in skeletal muscle from
insulin-resistant (type 2 diabetes mellitus [T2DM]) patients
[1-3]. A number of key mitochondrial genes determine the
balance between glucose and fatty acid metabolism [4],
including pyruvate dehydrogenase kinases (PDKs), carnitine
palmitoyltransferase (CPT1b, also known as CPT1muscle, CPT I,
CPT1-M, CPTI-M), and malonyl–coenzyme A (CoA) decarboxyl-
ase (MCD). The PDK enzymes phosphorylate the pyruvate
dehydrogenase complex, which leads to inhibition of the
complex and reduced carbohydrate oxidation. Thus, pyruvate
dehydrogenase complex inhibition is recognized as a flux
point at which fuel selection in skeletal muscle can be shifted
toward fat oxidation [5]. Four isoforms of PDK have been
identified in the human genome [6,7], and the primary
isoforms expressed in skeletal muscle are PDK2 and PDK4 [8].
Malonyl CoAdecarboxylase is a key enzyme regulating cellular
malonyl CoA levels [9], and malonyl-CoA is an allosteric
inhibitor of CPT1b [10]. Carnitine palmitoyltransferase 1b is
located at the outermitochondrialmembrane and controls the
transfer of long-chain fatty acid–CoA molecules from the
cytosol to the mitochondria where they are oxidized [10]. Like
the PDK enzymes, MCD and CPT1b also play a pivotal role in
fuel selection and drive increases in fatty acid oxidation.
The role of PDK4 in skeletal muscle has been examined
with various metabolic challenges. Pyruvate dehydrogenase
kinase 4 expression is increased in response to short-term
fasting [11] or high-fat diet [12], two circumstances that
increase the supply of lipids to skeletal muscle. Pyruvate
dehydrogenase kinase 4 transcription and PDK4 messenger
RNA (mRNA) are markedly increased in human skeletal
muscle during exercise of acute high intensity or prolonged
low intensity [13]. Increased PDK activity in skeletal muscle
suppresses glucose oxidation and thus may cause or exacer-
bate hyperglycemia. Mice with a targeted deletion of PDK4
have lower blood glucose levels and slightly improved glucose
tolerance as compared with wild-type mice after an 18-week
high-fat diet [14], highlighting a role of PDK4 in the develop-
ment of hyperglycemia. Furthermore, insulin exposure during
the euglycemic-hyperinsulinemic clamp reduces PDK4 mRNA
expression in normal glucose-tolerant (NGT), but not insulin-
resistant, people, indicating that elevations in PDK4 expres-
sion and activity may further increase plasma glucose levels
[15-17].
Malonyl-CoA decarboxylase and CPT1b also coordinate
fuel balance during exercise and states of metabolic disease.
Exercise reduces skeletal muscle malonyl-CoA [18,19] and
increases expression of MCD1 [19], which may contribute to
the increase in lipid oxidation at the onset of exercise [18].
Increased levels of malonyl-CoA have been reported in
insulin-resistant animal models [20]. However, MCD knock-
down protects against the development of dietary-induced
whole-body insulin resistance in mice [21] and enhances
insulin-stimulated glucose uptake in cultured human muscle
cells [9]. Carnitine palmitoyltransferase 1b expression and
function have been linked to the regulation of insulin
sensitivity. Chemical inhibition of CPT1b with the pharmaco-
logical agent etomoxir increases lipid deposition and exacer-
bates insulin resistance in rats fed a high-fat diet [22], whereas
overexpression of CPT1b in rat hind limb muscle by electro-
transfer prevents the dietary-induced insulin resistance on
glucose uptake [23]. Whether MCD or CPT1b levels are altered
or related to the metabolic phenotype in T2DM is unknown.
The aim of this study was to profile the expression pattern
of PDK4, PDK2, MCD1, and CPT1b in human skeletal muscle
from T2DM and matched NGT volunteers. We hypothesized
that lifestyle modification resulting in weight loss and
improved glycemic control would be accompanied by nor-
malization of these regulators of metabolic flexibility.
2. Materials and methods
2.1. Subjects
Type 2 diabetes mellitus (n = 33) patients and NGT (n = 79)
male and female volunteers were matched for age (61 ± 5
years) and body mass index (BMI) (30 ± 5 kg/m2). The ethics
committee at Karolinska Institutet approved all study pro-
tocols. Patients on insulin treatment and with symptomatic
coronary heart disease were excluded. The clinical character-
istics of the patients are presented in Table 1. All individuals
provided a muscle biopsy upon entry into the study.
2.2. Intervention program
This was a randomized controlled study. Volunteers were
randomized to the exercise or control group and asked to
maintain their usual eating habits. The participants in the
exercise group were instructed to increase their weekly level
of physical activity by 5 hours of walking with walking poles
(Nordic walking) for 4 months. They received instructions for
Nordic walking from a physiologist/personal trainer. Of the
total number of volunteers, a select group ofmale participants
in each category (n = 23, NGT; n = 17, T2DM) underwent an
exercise intervention and provided muscle biopsies before
and after exercise training.
2.3. Skeletal muscle biopsies
Skeletal muscle biopsies were obtained from subjects in the
morning, following an overnight fast. Local anesthesia
(lidocaine hydrochloride, 5 mg/mL) was administered, and
an incision (5mm long/10mmdeep) wasmade in the skin and
skeletal muscle fascia. A biopsy (20-100 mg) was obtained
from the vastus lateralis portion of the quadriceps femoris
using a conchotome tongue. Biopsies were immediately
frozen and stored in liquid nitrogen until analysis.
2.4. Human skeletal muscle cells
Skeletal muscle biopsies (rectus abdominis) were obtained
during scheduled abdominal surgery with informed consent
from the donors. The subjects were 61 ± 5 years of age, were of
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average weight (BMI, 26 ± 0.5 kg/m2), and had no known
metabolic disorders. The ethics committee at Karolinska
Institutet approved the study protocols. Satellite cells were
isolated from the biopsies by trypsin and collagenase diges-
tion and grown to confluent myoblasts that were differenti-
ated to myotubes as described [24,25]. Dulbecco modified
Eagle medium, Ham F-10 medium, fetal bovine serum,
penicillin, streptomycin, and Fungizone were obtained from
Gibco BRL (Invitrogen, Stockholm, Sweden). Unless specified,
all reagentswere purchased from Sigma (Stockholm, Sweden).
Radioactive reagents were purchased from Amersham.
2.5. mRNA expression analysis in muscle biopsies
Messenger RNA was prepared from vastus lateralis muscle
biopsies for gene expression analysis. Pure mRNA was
extracted from 30 mg of frozen tissue using a standard Trizol
extraction method (Invitrogen). Complementary DNA was
generated from 1 μg of mRNA using the High-Capacity cDNA
RT kit (Applied Biosystems, Stockholm, Sweden). Gene
expression analysis was carried out using a TaqMan-based
multifluidic card (MFC) gene expression assay (Applied
Biosystems, Foster City, CA). The following primer and probe
sets from Applied Biosystems were lyophilized in the MFC
well: MFC internal endogenous control 18S; Hs99999907_m1
(β2-microglobulin); Hs99999905_m1 (glyceraldehyde-3-phos-
phate dehydrogenase [GAPDH]); Hs00176865_m1 (PDK2);
Hs00176875_m1 (PDK4); Hs03046298_s1 (CPT1B [muscle]);
Hs00201955_m1 (MCD-1, MLYCD). Samples were applied
into the MCF well, and polymerase chain reaction (PCR)
amplification was performed using an Applied Biosystems
Prism 7900HT sequence detection system (Applied Biosys-
tems, Stockholm, Sweden). Messenger RNA was quantified
according to technical documents supplied by the manufac-
turer, and the relative abundance of target transcripts was
calculated after normalization of the data against the
housekeeping genes.
2.6. Immunoblot analysis
Aliquots of human skeletal muscle lysates (20 μg) were
resuspended in Laemmli buffer. Proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes (Bio-Rad, Danvers,
MA), blocked with 7.5% nonfat milk, washed with TBST (10
mmol/L Tris-HCL, 100 mmol/L NaCl, and 0.02% Tween 20), and
incubated with primary antibodies overnight at 4°C. Mem-
braneswerewashedwith TBST and incubatedwith appropriate
horseradish peroxidase–conjugated secondary antibodies (Bio-
Rad, diluted 1:25 000). Proteins were visualized by enhanced
chemiluminescence (GE Healthcare, Stockholm, Sweden). A
rabbit monoclonal antibody against PDK2 (catalog no. ab76152)
was purchased from Abcam (Cambridge, UK), and mouse
monoclonal antibody against MCD (catalog no. H00023417-
B01P) was purchased from Abnova (Taipei City, Taiwan).
2.7. mRNA expression analysis in cultured cells
Myotubes, prepared as described above, were washed 3 times
with RNase-free phosphate-buffered saline and then har-
vested directly for RNA extraction (RNeasy Mini Kit, Qiagen,
Sollentuna, Sweden). Total RNA concentration was measured
and reverse transcribed with random hexamers using the
high-capacity reverse transcription kit (Applied Biosystems).
Reactions were performed in duplicate in a 96-well format
using Prism 7000 Sequence Detector and TaqMan-based
technology (Applied Biosystems). TaqMan probes were pur-
chased from Applied Biosystems. Relative quantities of target
Table 1 – Anthropometric measurements and metabolic parameters in NGT and T2DM subjects
NGT T2DM Total NGT vs T2DM
N 79 33 112 P value
Sex (M/F) 30/49 24/9 66/69
Age (y) 60 ± 1 62 ± 1 61 ± 0.5 .165
Height (cm) 169.8 ± 1.0 174.2 ± 1.6 171.1 ± 0.9 .024
Waist circumference (cm) 98.4 ± 1.1 105.0 ± 1.6 100.3 ± 0.9 .001⁎
SBP (mm Hg) 136 ± 1.62 141.52 ± 2.26 137.63 ± 1.34 .060
DBP (mm Hg) 82.66 ± 0.89 81.82 ± 1.39 82.41 ± 0.75 .611
BMI (kg/m2) 29.8 ± 0.4 30.7 ± 0.6 30.1 ± 0.3 .246
FBG (mmol/L) 5.54 ± 0.05 8.08 ± 0.36 6.29 ± 0.16 <.001⁎
2-h BG (mmol/L) 7.20 ± 0.11 15.53 ± 0.59 9.66 ± 0.41 <.001⁎
HbA1c (%) 4.7 ± 0.0 6.1 ± 0.2 5.1 ± 0.1 <.001⁎
Insulin (pmol/L) 61.78 ± 4.04 69.71 ± 9.43 63.99 ± 3.91 .366
Cholesterol (mmol/L) 5.50 ± 0.09 4.71 ± 0.15 5.27 ± 0.09 <.001⁎
LDL (mmol/L) 1.63 ± 0.09 1.28 ± 0.14 1.52 ± 0.08 .002⁎
HDL (mmol/L) 3.32 ± 0.05 2.79 ± 0.06 3.17 ± 0.04 <.001⁎
C-peptide (nmol/L) 0.83 ± 0.03 1.05 ± 0.07 0.89 ± 0.03 <.001⁎
TG (mmol/L) 1.23 ± 0.06 1.38 ± 0.09 1.28 ± 0.05 .173
Apo A-I (g/L) 1.60 ± 0.03 1.38 ± 0.04 1.54 ± 0.03 <.001⁎
Apo B (g/L) 1.01 ± 0.02 0.93 ± 0.04 0.99 ± 0.02 .063
VO2 (L/min) 2.01 ± 0.07 2.07 ± .08 2.03 ± 0.06 .654
RQ 1.10 ± 0.01 1.08 ± 0.01 1.09 ± 0.01 .333
Data are presented as means ± SEM. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TG,
triglycerides; VO2, oxygen consumption; RQ, respiratory quotient. ⁎Significant at P < .01 level.
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transcripts were calculated after normalization of the data
using the standard curve method or comparative CT method.
2.8. Bisulfite sequencing
A subset of muscle biopsies derived from NGT and T2DM
subjects was selected for gDNA methylation analysis (age-
and BMI-matched male donors; n = 4, NGT; n = 4, T2DM).
Bisulfite treatment was performed as described [26], with the
following adaptations: 1 μg of genomic DNAwas embedded in
a 2% low–melting point agarose solution, and 10 agarose beads
were formed. A freshly prepared bisulfite solution (4 mol/L
sodium β-bisulfite, Sigma; 250 mmol/L hydroquinone, Sigma;
pH 5.0) was added to each reaction tube containing one single
bead. The reaction mixtures were incubated for 4 hours at
50°C under exclusion of light. Treatment was stopped by
equilibrations against 1 mL of Tris-EDTA (4× 15 minutes)
followed by desulfonation in 500 μL of 0.2 mol/L NaOH (2× 15
minutes). The reaction was neutralized, and beads were
washed with 1 mL Tris-EDTA (2× 15 minutes). Before the PCR
analysis, the beads were equilibrated against 1 mL of H2O (2×
30 minutes). For the amplification of regions +160 to +446 of
the PDK4 promoter, the following primerswere used: sense 5′-
GGT ATT TTT AAA TTT TAG TTT AGG T-3′, antisense 5′-ATC
CAA TAA CTA CTT CAT AAA CAA C-3′. The PCR fragments
were purified from an agarose gel using MinElute Gel
Extraction Kit (Qiagen) and cloned into pDrive vector using a
PCR cloning kit (Qiagen) according to the manufacturer's
protocol. Individual clones were grown, and plasmids were
purified using QIAprep Spin Miniprep Kit (Qiagen). For each
condition, 10 to 50 clones were sequenced using T7 promoter
primer on an ABI 3730xl DNA Analyzer platform at Cogenics
(Hope End, UK).
2.9. Statistical analysis
All data are presented as mean ± SEM. Baseline differences in
gene expression between NGT subjects and T2DM patients
were analyzed using an independent t test. Pearson correla-
tions were calculated for baseline measurements of gene and
clinical parameters. Regression models controlled for covari-
ates (age, sex, and BMI) were used to examine clinical
predictors of gene expression. Computation of the fold change
following exercise intervention was performed using a paired
t test. Comparisons were considered statistically significant at
P < .05. Natural log transformation was applied when data
were not normally distributed. Analyses were performed
using SPSS version 17.0 (SPSS, Chicago, IL).
3. Results
3.1. PDK4, PDK2, and MCD1 mRNA expression is
increased in skeletal muscle from T2DM patients
We measured skeletal muscle mRNA expression of PDK4,
PDK2, CPT1b, and MCD1 in T2DM and in age- and BMI-
matched NGT subjects (clinical characteristics are reported in
Table 1). Skeletal muscle mRNA expression of PDK4 was
increased approximately 70% (P < .01) in T2DM patients as
compared with BMI- and age-matched NGT volunteers (Fig.
1A). Messenger RNA expression of PDK2 and MCD1 was
increased approximately 50% in skeletal muscle from T2DM
patients (Fig. 1B-C, P < .05). In contrast, mRNA expression of
CPT1b was similar between cohorts. Protein expression of
PDK2 and MCD was determined in a subset of subjects where
material permitted (Fig. 1E). Protein levels support the
observed mRNA expression patterns. Antibody detection of
protein levels of PDK4 and CPT1b using commercially
available antibodieswas unsuccessful, with antibodies detect-
ing several nonspecific bands.
3.2. Skeletal muscle mRNA expression of PDK4 correlates
with BMI and with PDK2, CPT1, and MCD mRNA expression
Skeletal muscle PDK4 mRNA expression was positively corre-
lated with BMI (represented graphically in Fig. 2B), waist
circumference, fasting and 2-hour blood glucose, hemoglobin
A1c (HbA1c), insulin, and circulating C peptide in the entire
cohort of study participants (n = 112, Table 2). The differential
clustering pattern of NGT and T2DM subjects may suggest a
tighter relationship between PDK4 mRNA and BMI in the
presence of maintained glucose regulation. Pyruvate dehydro-
genase kinase 4 mRNA expression was negatively correlated
(P < .05) with cholesterol and low-density lipoprotein (LDL).
Pyruvate dehydrogenase kinase 2 mRNA was positively corre-
lated with fasting and 2-hour blood glucosemeasurements (P <
.05), and negatively correlated with diastolic blood pressure,
high-density lipoprotein (HDL) and apolipoprotein (apo) A-I.
Malonyl-CoA decarboxylase was inversely correlated with HDL
and apo A-I (Table 2, P < .05). Messenger RNA expression of the
mitochondrial genes was positively and highly correlated (r =
0.246-0.889, P < .001),with the strongest correlation observed for
expression of PDK2 and MCD (Fig. 2A, r = 0.889, P < .0001).
Multiple regression analysis revealed that BMI is associated
with PDK4 gene expression after adjustment for age, sex, and
diabetes status (Table 3). Regression models demonstrate that
the relationship between PDK4 and BMI was significant,
independent of age, sex, cohort, and glucose tolerance. After
correcting for age, sex, and cohort, the expression of PDK4
remained independently determined by BMI (r = 0.348, P = .002).
Although theexpressionof thegenes correlatedhighly, similarly
strong relationships did not exist between other genes and the
clinical factors after controlling for age, sex, and cohort.
3.3. PDK4 promoter methylation is reduced in skeletal
muscle from T2DM patients
Using bisulfite sequencing, we determined the methylation
status of cytosines in the +160 to +446 region of the PDK4
promoter in skeletal muscle from T2DM patients and NGT
volunteers. The increase in PDK4 mRNA expression noted in
the T2DMpatients was accompanied by a parallel reduction in
PDK4 promoter methylation (Fig. 3).
3.4. Effect of lifestyle modification on skeletal muscle
mRNA expression
We further determined the effect of a 4-month lifestyle
intervention involving approximately 4 hours of Nordic
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walking a week on skeletal muscle mRNA expression in a
subgroup of this population. Walking exercise was associated
with modest weight loss in NGT and T2DM subjects (P < .05;
Table 4). In the T2DM patients, weight loss was accompanied
by a reduction in 2-hour plasma glucose levels, whereas in the
NGT subjects, the fasting plasma insulin level was reduced.
Skeletal muscle PDK4 mRNA expression was increased in
response to lifestyle intervention, but only in NGT subjects
(Fig. 4A). Although PDK4 expression in skeletal muscle was
elevated in T2DM before the exercise intervention (Fig. 1A), no
further increase was noted upon the completion of the
intervention program. Skeletal muscle mRNA expression of
PDK2, MCD1, or CPT1b was unaltered by the lifestyle
intervention program (Fig. 4 B-D).
3.5. Regulation of mRNA expression of PDK4, PDK2,
CPT1b, and MCD1 in cultured human muscle cells
We determined mRNA expression of PDK4, PDK2, CPT1b, and
MCD1 in cultured skeletal muscle following 48 hours of
incubation in the presence of 3 mmol/L caffeine, 1 mmol/L
AICAR, or 200 μmol/L palmitate. These agents were selected to
mimic metabolic conditions generated in skeletal muscle
during exercise, such as increased Ca2+ (induced in cultured
muscle following exposure to caffeine [27]), activation of
AMPK [28], or increased lipids. Caffeine and palmitate
independently increased mRNA expression of PDK4 approx-
imately 40-fold and 15-fold, respectively (Fig. 5A). Caffeine
exposure increased mRNA expression of PDK2 approximately
50% (P < .05; Fig. 5B). Palmitate exposure increases CPT1
mRNA, whereas MCD1 expression increased in response to
both caffeine and palmitate (Fig. 5C, D).
4. Discussion
Type 2 diabetes mellitus is associated with abnormal
substrate metabolism, raising the possibility that alterations
in the expression of mitochondrial enzymes controlling lipid
uptake and metabolism may by altered. Here we determined
skeletal muscle expression of key mitochondrial genes that
orchestrate the switch of substrate utilization between
glucose and lipid sources. We show that mRNA expression
of PDK4, PDK2, and MCD1 is upregulated in human skeletal
muscle from T2DM patients. We have previously demon-
strated that reduction of MCD1 enhances glucose and
reduces lipid metabolism in cultured human muscle cells
[9]. Thus, increased MCD1 expression may play a role in
reducing skeletal muscle glucose utilization in glucose-
intolerant individuals.
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Elevated PDK4 gene expression corresponds with various
clinical phenotypes. Circulating lipid levels have been
highlighted as a key factor determining PDK4 expression [5].
In rats, a 4-week high-fat diet increases PDK4 mRNA
expression [29]. In our study, plasma triglyceride levels were
unaltered between NGT volunteers and T2DM patients; and
thus, PDK4 mRNA expression was unrelated to triglyceride
levels. A subset of the T2DM patients in the present
study regularly used cholesterol-lowering medications or
other pharmacological interventions, which may mask such
relationships. Messenger RNA expression of PDK4 is also
acutely regulated by insulin [17,30]; and thus, the increased
PDK4 mRNA in the T2DM patients may be a consequence of
hyperinsulinemia and insulin resistance at the level of the
enzyme, such that expression is not appropriately sup-
pressed. Reductions in skeletal muscle glycogen is known to
increase PDK4 mRNA [31]. Although muscle glycogen content
was not determined, PDK4 was positively correlated with
fasting glucose levels. However, a significant correlation
between PDK4 mRNA expression and BMI highlights the
relationship between the expression of mitochondrial genes
related to lipid metabolism and body mass. Examination of
gene-gene correlations revealed positive relationships be-
tween PDK4, PDK2, CPT1b, and MCD in the entire study cohort
(Table 2), further supporting that this cluster of genes is
similarly coordinated and regulated in healthy and diseased
individuals. The inverse correlation noted between PDK4
methylation and PDK4 expression in skeletal muscle suggests
the possibility that epigenetic modification orchestrates the
regulation of mitochondrial genes involved in substrate
switching. Although the verification of PDK4 regulation at
the protein level would further strengthen this finding, we
were unable to reliably detect PDK4 protein using currently
available antibodies. Our analysis of PDK2 and MCD protein
reflects the increase noted in mRNA levels. Because the
elevation of these genes at the mRNA level correlates highly
(Fig. 2A), this suggests that an increase in PDK4 transcript may
consequently result in an end-point increase in protein
expression also, as has been reported for the majority of
mammalian genes [32]. Collectively, our findings provide
evidence that the level of PDK4 gene expression reflects
glucose/lipid metabolism, which is possibly potentiated by
epigenetic control.
A 4-month lifestyle modification program increased skel-
etal muscle PDK4 mRNA expression in NGT subjects, but was
without effect on PDK4 expression in T2DM patients. This
differential response could be due to a higher compliancewith
the exercise program in the NGT subjects or to an inability of
the T2DM patients to appropriately respond to the exercise
training program. Pyruvate dehydrogenase kinase 2, CPT1b, or
MCD gene expression was unaltered following exercise
intervention in our study, indicating a set level of stability
and/or a resistance of fluctuation in response to this particular
exercise stimulation. However, the understanding of the
overall metabolic regulation of PDK4 is complicated by
seemingly conflicting results, as an elevation is observed
both in T2DM and following exercise intervention. The
apparent paradox of skeletal muscle lipid metabolism in
states of insulin resistance vs exercise training has been
discussed previously [33].
Conditions of obesity and insulin resistance are strongly
associated with impaired rates of fatty acid oxidation in
skeletal muscle [34]. Further indication of high fatty acid
availability is a buildup of intramyocellular lipids (IMCL),
which reflects an elevated fatty acid flux into the muscle
[35,36]. Thus, our finding that PDK4mRNA is elevated in T2DM
and correlates with BMI further supports that an elevated lipid
flux in an insulin-resistant state requires an upregulation of
gene pathways involved in the switch from carbohydrate to
lipid oxidation. However, the molecular pathways involved in
lipid uptake and storage are not entirely transparent, as the
muscle of highly trained athletes also contains excess IMCL
[33]. The observation that PDK4 is elevated after exercise,
concomitant with an observed decrease in BMI, may appear
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contradictory given the positive correlation between PDK4
and BMI observed at baseline. However, reports examining the
effects of exercise on skeletal muscle fatty acid transport and
oxidation, particularly low-intensity exercise, demonstrate a
high reliance of themuscle on lipid sources of fuel [37,38]. The
initiation of exercise mobilizes FFAs from adipose tissue as a
fuel source [39], and subsequent oxidation in muscle mito-
chondria requires increased participation of relevant players
involved in the metabolic switch [40]. Thus, as with states of
insulin resistance, exercise intervention elicits an increase in
PDK4 expression in NGT subjects, reflecting a metabolic
adjustment to prioritize lipid fuel handling. We did not
observe a PDK4 elevation in T2DM following exercise, which
Table 2 – Correlation analysis between skeletal muscle mRNA expression and clinical parameters in NGT and T2DM
subjects
PDK4 mRNA PDK2 mRNA CPT1b mRNA MCD mRNA
r P value r P value r P value r P value
PDK4 mRNA – – 0.278† .003 0.246 † .009 0.374† <.001
PDK2 mRNA 0.278† .003 – – 0.637 † <.001 0.889† <.001
CPT1b mRNA 0.246† .009 0.637† <.001 – – 0.689† <.001
MCD mRNA 0.374† <.001 0.889† <.001 0.689 † <.001 – -
Height (cm) −0.066 .489 0.061 .520 −0.117 .221 −0.046 .631
Waist circumference (cm) 0.328† <.001 −0.033 .730 −0.141 .140 −0.065 .496
SBP (mm Hg) 0.057 .550 0.005 .956 0.009 .925 0.025 .792
DBP (mm Hg) −0.045 .641 −0.203 ⁎ .032 −0.087 .364 −0.192 ⁎ .042
BMI (kg/m2) 0.319† .001 −0.010 .919 0.006 .950 0.030 .752
FBG (mmol/L) 0.248† .008 0.198 ⁎ .037 0.149 .120 0.185 .050
2-h BG (mmol/L) 0.284† .002 0.227 ⁎ .016 0.149 .120 0.198 ⁎ .036
HbA1c (%) 0.251† .008 0.165 .083 0.089 .352 0.147 .122
Insulin (pmol/L) 0.263 ⁎ .011 0.107 .306 0.085 .422 0.190 .068
Cholesterol (mmol/L) −0.241 .022 −0.105 .270 −0.030 .757 −0.057 .548
LDL (mmol/L) −0.186 ⁎ .050 −0.029 .761 0.045 .641 0.007 .939
HDL (mmol/L) −0.155 .103 −0.224 ⁎ .018 −0.216 ⁎ .022 −0.156 .102
C-peptide (nmol/L) 0.328† <.001 0.053 .580 0.077 .420 0.081 .395
Apo A-I (g/L) −0.104 .274 −0.230 ⁎ .014 −0.243 ⁎ .010 −0.185 .051
Apo B (g/L) −0.067 .482 −0.069 .472 0.055 .563 −0.012 .898
VO2 (L/min) −0.048 .622 0.080 .410 0.156 .107 0.052 .588
RQ −0.076 .435 −0.183 .056 0.033 .737 −0.115 .232
⁎ Significant at P < .05 level.
† Significant at P < .01 level.
Table 3 –Multiple regression analysis between age, sex,
BMI, and PDK4 mRNA expression in NGT and T2DM
subjects
PDK4
β-Coefficient P value
Model 1
Age 0.023 .132
Sex −0.065 0.685
Cohort 0.208 .020 ⁎
BMI 2.296 .002†
Model 2
Age 0.022 .154
Sex −0.066 .683
Cohort 0.143 .443
BMI 2.285 .002†
2-h BG 0.176 .689
Model 3
Age 0.018 .305
Sex 0.006 .972
Cohort 0.227 .016 ⁎
BMI 1.731 .029 ⁎
Insulin 0.342 .026 ⁎
⁎ Significant at P < .05 level.
† Significant at P < .01 level.
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may signify that this exercise intervention was not of
sufficient intensity to elicit a response in insulin-resistant
participants. An examination of IMCL was not performed in
this study.
The expression of the FAT/CD36 transporter in skeletal
muscle reflects a similar pattern of regulation as we report for
PDK4. Increases in FAT/CD36 mRNA and/or protein have been
observed in human obesity, in T2DM [41], and after a high-fat
diet [42,43]. Elevation in FAT/CD36 transporter levels in
skeletal muscle is also observed following exercise training,
through a proposed metabolic adaptation of greater fuel
utilization [44]. Thus, an increase in expression of genes
involved in the switch of fuel sources could be expected in two
contrary circumstances, both of which require similar molec-
ular orchestration to balance an elevated fatty acid influx.
DNA methylation alters gene transcription by regulating
the accessibility of the transcription factors and transcription
machinery to the DNA strand. Whether the differential
exercise-dependent mRNA change in PDK4 is related to the
difference in PDK4 promoter methylation noted between NGT
and T2DM patients remains to be investigated. Increased
promoter methylation of peroxisome proliferator-activated
receptor γ coactivator 1α (PGC1α), another key regulator of
mitochondrial activity, has been reported in skeletal muscle
from people with impaired glucose tolerance or T2DM [45] and
in subjects with low birth weight [46]. Furthermore, exposure
of cultured muscle cells to fatty acids [45] or to a high-fat diet
in low-birthweight men [46] increases PGC1α promoter
methylation. Whether PDK4 promoter methylation is similar-
ly regulated remains to be determined. However, here we
provide evidence that reduced PDK4 promoter methylation is
associated with metabolic disease, whereas our previous
study established that PGC1α promoter methylation is
Table 4 – Anthropometric measurements and metabolic parameters in NGT and T2DM men before and after exercise
training
Pre ± SEM Post ± SEM Δ ± SEM P value
Pre vs post Pre, NGT vs T2DM Δ, NGT vs T2DM
N NGT 23
T2DM 17
Age NGT 61 ± 1
T2DM 62 ± 1 .253
Weight (kg) NGT 89.9 ± 2.04 88.5 ± 2.16 −1.39 ± 0.43 .003†
T2DM 94.1 ± 2.74 92.5 ± 2.71 −1.54 ± 0.59 .018 ⁎ .220 .830
BMI (kg/m2) NGT 28.7 ± 0.43 28.1 ± 0.46 −0.57 ± 0.15 .001†
T2DM 29.9 ± 0.81 29.5 ± 0.78 −0.44 ± 0.20 .042 ⁎ .184 .628
Waist circumference (cm) NGT 101.57 ± 1.63 98.00 ± 1.64 −3.57 ± 0.54 <.0001 †
T2DM 105.11 ± 2.05 103.06 ± 2.07 −2.06 ± 0.63 .005† .178 .076
FBG (mmol/L) NGT 5.57 ± 0.11 5.48 ± 0.11 −0.09 ± 0.11 .434
T2DM 8.32 ± 0.52 8.01 ± 0.52 −0.32 ± 0.24 .207 <.0001† .407
2-h BG (mmol/L) NGT 7.07 ± 0.22 6.84 ± 0.27 −0.23 ± 0.26 .392
T2DM 15.11 ± 0.82 13.37 ± 1.00 −1.73 ± 0.55 .006† <.0001† .021 ⁎
Insulin (pmol/L) NGT 65.82 ± 6.91 44.76 ± 4.01 −17.33 ± 5.02 .003†
T2DM 88.19 ± 12.93 87.07 ± 13.35 10.06 ± 12.91 .917 .139 .066
VO2 (L/min) NGT 2.46 ± 0.14 2.61 ± 0.12 0.15 ± 0.12 .249
T2DM 2.13 ± 0.12 2.22 ± 0.12 0.03 ± 0.15 .872 .102 .540
Nordic walking (h/wk) NGT 4.895 ± 0.34
T2DM 4.061 ± 0.38 .110
⁎ Significant at P < .05 level.
† Significant at P < .01 level.
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Fig. 4 – Effects of exercise on gene expression. The relative
change in skeletal muscle mRNA expression of PDK4 (A),
PDK2 (B), CPT1b (C), and MCD (D) mRNA in age- and
BMI-matched NGT and T2DM subjects following a 4-month
lifestyle intervention program. Values are means ±
SEM (*P < .05).
182 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 1 ( 2 0 1 2 ) 1 7 5 – 1 8 5
increased [45]. This suggests that alteredmethylation patterns
associated with metabolic disease may be promoter specific.
Weight loss is accompanied by a marked reduction in
skeletal muscle PDK4 expression following surgery-induced
weight reduction [47,48], and the depression in PDK4 expres-
sion has been correlated to improvements in insulin sensi-
tivity [47]. Here we note that BMI is associated with PDK4
expression independent of age, sex, or state of glucose
tolerance. A diet-mediated weight reduction program, result-
ing in a stabilized 10% weight loss, was associated with a
nonsignificant tendency for reduced skeletal muscle PDK4
expression [49]. The weight loss achieved following lifestyle
intervention in the present study was relatively modest (1.5
kg), yet PDK4 mRNA was elevated in NGT subjects after
exercise training. This finding perhaps reflects a modulation
of fuel selection. Although PDK4 has been highlighted as a
point of dysregulation in the context of T2DM and obesity
[17,50], the overall impact of a loss of PDK4 is surprisingly
slight. Mice lacking PDK4 have a modest reduction in fasting
glucose and are slightly more glucose tolerant than wild-type
mice after 16 weeks on a high-fat diet [14]. Clearly, PDK4 is
only recognized in certain circumstances as a key regulator of
glucose vs lipid utilization. For example, we have recently
reported that in response to exposure to glucocorticoids,
skeletal muscle cultures increase lipid oxidation and reduce
glucose metabolism; and a key mediator of this response is
induction of PDK4 expression [51].
The role of mitochondria in metabolic disease, and
whether increasing fatty acid flux into muscle mitochondria
reduces or exacerbates insulin sensitivity, is the subject of
debate [52-55]. One crucial role in muscle mitochondrial
function may be the ability to adapt to or show a preference
for different fuel substrates, that is, the flexibility of the
muscle to adapt to altered environments [1]. Because the same
lifestyle modification program in NGT subjects increased
skeletal muscle PDK4 expression, the final PDK4 expression
noted in T2DM patients may be appropriate for the level of
substrate demand placed on the muscle as a result of the
increased exercise performed. To dissect the relative impact of
different exercise-associated factors, we exposed cells in
culture to agents that increase intracellular Ca2+ (caffeine
[27]), activate AMPK [28], or change the lipid supply to mimic
exercise-dependent increase in circulating fatty acids. Acti-
vation of AMPK (in response to AICAR) was insufficient to
induce alterations inmRNA expression of these genes. In fact,
no single agent resulted in a coordinated increase in
expression of the genes under study; however, caffeine
exposure led to a profound increase in PDK4. Indeed, caffeine
exposure resulted in increased expression of PDK4, PDK2 and
MCD, which were also increased in skeletal muscle from the
T2DM patients. Whether intracellular Ca2+ signaling is en-
hanced in T2DM is unknown. However, because caffeine
exposure in cultured muscle resulted in a profound (40-fold)
increase in PDK4 mRNA, the lack of exercise-dependent
induction of PDK4 in diabetic muscle would argue against
enhanced Ca2+ signaling in diabetic skeletal muscle.
In conclusion, we provide evidence that expression of key
enzymes regulatingmitochondrial function in skeletal muscle
is altered in T2DM patients. Increased expression of PDK4
mRNAwas coincident with decreased PDK4 promotermethyl-
ation, indicative of epigenetic regulation. In addition, a
lifestyle intervention involving low-intensity exercise
resulted in increased expression of PDK4 mRNA in NGT
volunteers but not T2DM patients, possibly implicating
resistance to the appropriate adaptive responses to exercise
and changes in metabolic demands in skeletal muscle
associated with insulin resistance.
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Fig. 5 – Effect of exercise mimetics on gene expression. Effect
of caffeine, AICAR, and palmitate treatment on mRNA
expression of PDK4, PDK2, CPT1b, and MCD (A, B, C, and D,
respectively) in cultured human skeletal myotubes.
Differentiated myotubes were incubated in the absence or
presence of caffeine (3 mmol/L, 48 hours), AICAR (1 mmol/L,
18 hours), or palmitate (200 μmol/L, 48 hours) before the
extraction of total RNA. Results are reported as a relative
expression related to B2M mRNA. Values are means ±
SEM (*P < .05).
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